TW413633B - Amino acid composition - Google Patents

Amino acid composition Download PDF

Info

Publication number
TW413633B
TW413633B TW086100261A TW86100261A TW413633B TW 413633 B TW413633 B TW 413633B TW 086100261 A TW086100261 A TW 086100261A TW 86100261 A TW86100261 A TW 86100261A TW 413633 B TW413633 B TW 413633B
Authority
TW
Taiwan
Prior art keywords
amino acid
mole
acid
ear
blood
Prior art date
Application number
TW086100261A
Other languages
Chinese (zh)
Inventor
Takeshi Abe
Hiroshi Tsuchida
Koji Iida
Original Assignee
Rikagaku Kenkyusho
Meiji Milk Prod Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rikagaku Kenkyusho, Meiji Milk Prod Co Ltd filed Critical Rikagaku Kenkyusho
Application granted granted Critical
Publication of TW413633B publication Critical patent/TW413633B/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The present invention relates to an amino acid composition which contains the following amino acids in the following molar ratio. Proline (12.6-23.4), alanine (8.4-15.6), glycine (13.3-24.9), valine (8.2-15.4), threonine (5.0-9.4), leucine (4.3-8.1), histidine (1.8-11.9), serine (1.7-3.3), lysine (6.0-11.2), isoleucine (3.1-5.9), glutamic acid (2.2-10.4), arginine (2.4-4.6), phenylalanine (2.6-5.0), tyrosine (4.2-7.8), and trypsin (1.5-2.9). The amino acid composition has an effect for supplementing the decrease of blood-leveled amino acids due to strong physical exercises, reducing the changes in the concentrations of the blood-leveled amino acids, improving motion mechanisms or reducing fatigue after excise, and recovering from the fatigues.

Description

本 ΐ;α'·': ;ττ·χ 原1:質内容 經濟部中夬樣隼局員工消費合作社印获 附件Ben ΐ; α '·':; ττ · χ Original 1: qualitative content Printed by the Employee Consumer Cooperatives of the Bureau of Samples in the Ministry of Economic Affairs

(抑制血液中胺基酸組成之變化並提升其保持效果) 本試驗乃藉家鼠為試驗動物,證實運動前投與VAAM可 抑制®動時血液中按基酸S度降低之效果。 以家鼠(Sprague Dawley rats,雄鼠,6遇龄,每群 3隻,平均體重為190g)為試驗動物,經禁食一夜後,將 表2所示从64»,04丨》&lt;(酪朊胺基酸混合物)調製成3.8重董 *之水溶液或蒸《水0.4·丨經口投與,然後在室租下休息 30分鐘。繼之.藉傾斜7°的馬達驅勡蓮動設備(每分鐘 23公分)抱步90分鐘。分别在投舆前30分鐘、抱步開始時 、雎步45分鏡時、抱完90分鐘時分別採取血液試料,鼸定 其乳酸、«萄糖,及非酯化脂肪酸(KEFA)濃度。非抱步群 則除了未抱步外,其他完全施舆苘樣處理並進行同樣的分 析。结果分別示於第8園〜第12鼸。 第8圏〜第10圖示投舆VAAM, CAAM或蒸皤水對於家鼠 血掖中《萄糖義度,血掖中乳酸《度及血液中非酯化脂肪 酸濃度之影《。第8圈〜第10鼷中,U)示抱步群,(b)示 非抱步群。星形符St表舆VAAM投輿群比較杲顯示有意差異 (P&lt;0 . 05)之结果。 由第8圃&lt;a)可知,血液中《菊糖濃度,以CAAM或蒸 籣水投與群顴示稍离情形,但鶄抱步45分鐘及90分鐘後卽 顯示有意義的降低。相對而言,VAAH投與群在抱步45分鏟 時不會降低,抱步90分饞後也較之其他之投舆群顯示有意 差異(p&lt;〇.05)的較离结果。非抱步群[第8黼(b)]之血液 本紙張尺度遑用中國囷家標準(CNS)A4况格(210X297公釐) 20{修正頁) 38635 (請先閲讀背面之注意事項再填寫本頁} 如633 Μ Β7 經濟部中央標苹局員工消资合作社印製 五、發明説明( 1 ) 本 發 明 像 有 關 由 胡 蜂 雄 腾 (V e s p a 靥 )之幼蟲所分泌唾液 1 1 I 中 之 胺 基 酸 類 組 成 之 資 訊 中 所 捎 得 之 胺 基 酸 組 成 物 者 〇 詳 1 1 之 » 本 發 明 有 關 具 有 可 補 充 因 激 烈 運 動 而 引 起 之 血 液 1 I 請 I 中 胺 基 酸 的 減 少 有 肋 於 提 升 運 動 能 减 輕 蓮 動 後 之 疲 先 聞 ί [ 勞 及 恢 復 疲 勞 等 功 能 的 胺 基 酸 組 成 物 1 以 及 含 有 該 組 成 物 背 面 1 r 之 t 的 補 液 者 0 意 l 事 1 已 往 罕 見 有 閘 胡 蜂 幼 蟲 之 研 究 報 告 1 恃 別 是 胡 蜂 幼 蟲 再 1 填 1 所 分 泌 唾 液 的 研 究 報 告 幾 乎 不 存 在 t 該 唾 液 之 組 成 兀 全 不 窝{ 本’ l· c 1 詳 〇 丽 且 m 於 胡 蜂 之 驚 人 的 蓮 動 耐 久 力 究 竟 换 由 何 種 營 養 頁 1 ! 所 促 成 % 則 更 是 完 全 不 瞭 解 C i I 本 發 明 研 究 者 從 事 各 種 胡 蜂 幼 蟲 所 分 泌 唾 液 之 研 究 » 1 1 解 明 構 成 唾 液 之 組 成 發 現 該 組 成 物 能 極 有 效 地 調 節 脂 質 n 1 \ 醣 類 之 代 謝 作 用 » 並 解 明 該 有 效 成 分 0 現 在 已 發 現 以 經 J 1 1 q 方 式 服 用 胡 蜂 幼 蟲 所 分 泌 的 胺 基 酸 營 養 液 時 具 有 m 節 蓮 1 I 動 時 脂 質 和 糖 類 的 代 謝 作 用 (參照日本專利中例如恃開平 1 1 ( % 3 - 128318號 公 報 1 待 開 平 4 - 9 5 0 2 6號公報, 待開平4 - \ ! 1 1 2 8 2 5 ¾ 公 報 ψ 特 開 平 4 ~ 1 2 0 0 2 0 號 公 報 )0 1 i 本 發 明 研 究 者 已 經 解 明 胡 蜂 營 養 液 能 抑 制 運 動 時 疲 劳 1 1 物 質 的 産 生 1 SJ 防 止 血 糖 值 之 下 降 * 更 能 有 助 於 運 動 能 力 1 l 之 提 升 0 上 述 作 用 機 制 顯 示 可 促 m 利 用 脂 肪 做 為 運 動 所 1 I 能 源 所 造 成 〇 作 為 該 普 養 液 主 要 成 分 之 胡 蜂 胺 基 酸 混 合 物 i \ 1 (V e s pa in i no a c i d mi X t u r e , 簡稱為V A A Μ )己 知 除 上 述 作 1 I 1 用 外 亦 具 有 恢 愎 因 運 動 而 引 致 疲 勞 之 功 能 等 種 種 其 他 效 1 1 果 0 運 動 所 迪 成 的 疲 勞 已 知 肯 引 起 血 液 中 的 胺 基 m 大 幅 度 1 1 本紙張尺度適用中國國家標準(CMS ) Λ4坭格(210X297公釐) 3 3 8 8 3 5 413633 B7 經濟部中央榡準局負工消f合作社印製 五、· 發明説明(2 ) 1 失 去 原 有 平 衡 0 疽 種 失 去 平 衡 現 象 被 認 為 是 伴 隨 運 動 而 來 1 1 | 的 逆 境 (S t Γ e s S)所谄 成 身 體 組 餓 之 磨 損 和 破 壞 之 結 果 〇 然 1 1 I 而 到 現 在 為 止 r 很 少 有 人 注 意 其 生 理 上 的 意 義 和 重 要 性 0 1 I 請 \ 本 發 明 研 究 者 研 究 運 動 後 血 液 中 胺 基 酸 瀑 度 和 胡 蜂 胺 先 Μ 1 AS 1 I 基 酸 混 合 物 之 胺 基 酸 組 成 之 結 果 1 發 現 VAAH 之 胺 基 酸 組 成 背 1¾ 1 t 之 1 與 因 蓮 勘 疲 勞 而 造 成 之 血 液 中 胺 基 酸 的 減 少 有 極 重 大 的 相 注 意 [ I 事 1 朗 m % 〇 換 之 » 因 疲 勞 而 引 起 愈 多 的 胺 基 酸 滅 少 時 9 其 項 再 1 填 1 在 V A Α Η Φ 的 含 量 也 會 愈 多 0 寫( 本 t 入 頁 1 對 於 運 動 機 能 之 提 升 和 疲 勞 之 恢 愎 1 上 述 所 減 少 胺 基 、~- ί I 酸 之 補 充 rrftr 是 不 可 欠 缺 之 方 法 之 — 0 因 此 f 本 發 明 人 等 乃 1 1 根 據 上 述 人 在 蓮 動 疲 勞 時 所 減 少 的 血 中 胺 基 酸 和 V A AM 中 之 1 1 胺 基 酸 組 成 有 極 高 相 m 關 % 之 事 實 之 發 現 作 進 — 步 之 研 究 訂 1 因 而 兀 成 本 發 明 〇 I 本 發 明 之 百 的 在 提 供 — 種 胺 基 酸 組 成 物 ψ 恃 別 是 含 有 1 1 該 胺 基 酸 組 成 物 之 補 液 者 〇 該 胺 基 酸 組 成 物 或 補 液 可 補 充 1 1 ( 随 伴 運 動 而 産 生 之 血 液 中 胺 基 酸 的 滅 少 i 具 有 提 升 運 動 機 \ 1 能 減 輕 運 動 疲 努 和 恢 後 疲 勞 等 效 果 0 1 1 本 發 明 之 另 一 巨 的 在 提 供 可 抑 制 伴 隨 激 烈 運 動 所 m 成 1 1 血 液 中 胺 基 酸 濃 度 之 變 動 並 提 升 其 保 持 之 方 法 i 以 及 該 方 1. 法 中 所 使 用 之 胺 基 酸 組 成 物 持 別 是 含 有 該 胺 基 酸 Μ 成 物 1 | 之 補 液 0 1 ! 本 發 明 之 胺 基 酸 組 成 物 (下文Ί =或簡稱為H V A AM )含有 1 1 I 下 列 契 耳 比 率 的 胺 基 酸 * 1 1 晡 胺 酸 12 .6 2 3 .4 莫耳 1 1 本紙張尺度適用中囷國家標皁(CNS ) Λ4規格(2!0X 297公釐) 413633 A7 B7 經濟部中央標準局負工消费合作社印製 五、發明説明( 3 ) I I 丙 胺 酸 8 .4〜 15.6 Μ 耳 1 1 I 甘 胺 酸 13 ,3〜 24.9 Μ 耳 1 1 1 纈 胺 酸 8 &gt; 2〜 15.4 Μ 耳 1 1 請 1 I 蘇 胺 酸 5 .0〜 9.4 Μ 耳 先 Μ Ί 1 | 白 胺 酸 4 ,3〜 8.1 契 耳 背 1 之 1 組 胺 酸 1 ,8〜 11.9 莫 耳 注 意 京 1 | 絲 胺 酸 1 ,7〜 3,3 其 耳 項 再 1 1 離 胺 酸 6 -0〜 11.2 吴 耳 耸( 本 t- 页 1 異 白 胺 酸 3 ]〜 5.9 契 耳 ί f 胺 酸 2 • 2〜 10.4 Μ 耳 1 1 精 胺 酸 2 ,4〜 4.6 契 耳 1 ! 苯 丙 胺 酸 2 • 6〜 5,0 Μ 耳 訂 i 酪 胺 酸 4 .2〜 7,8 莫 耳 ! 1 色 胺 酸 1 • 5〜 2,9 Μ 耳 1 1 本 發 明 亦 偽 有 關 以 Η V A A Μ投與晡乳動 物而提供抑制伴 1 1 ( % m 運 動 所 引 起 之 血 液 中 胺 基 酸濃 度變 動之方 法 0 1 本 發 明 更 包 含 V A AM 之 m 基酸 組成 ,或各 構 成 胺基 酸 契 1 1 耳 bb 率 在 加 減 30 % 範 圍 比 率 内變 化之 胺基酸 組 成 物, 其 中 1 ! 以 m 化 範 圍 在 士 20 % 為 較 宜 ,鑛 好在 士 1 〇 % 範 圍 内费 化 者 1 1 0 換 之 本 發 明 包 含 按 照 下列 奠耳 ϋ率的 胺 基 酸所 構 成 1 I 1 而 提 供 抑 制 伴 隨 運 動 所 引 起之 血液 中胺基 酸 濃 度變 動 之 1 | 用 途 的 胺 基 m 組 成 物 (下文中 1 ,總稱ϋ -種 胺菡酚組成物為 1 1 I V AAH), 以及投與該胺基酸袖 1成物給哺 ί乳 動物為持尠, 而 I 1 提 供 抑 制 伴 随 運 動 所 引 起 血 液中 胺基 酸餵度 變 動 之方 法 C 1 1 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X297公釐) 5 3 8 6 3 5 «3633 A7 B7 五、發明説明( 經濟部中央橾準局員工消费合作社印取 脯 胺 酸 12 .6 23 .4 某耳 丙 胺 酸 4 .2 «V 7 .8 莫耳 甘 胺 酸 13 .3 24 .9 契耳 纈 胺 酸 4 .1 7 .7 莫耳 蘇 胺 酸 5 .0 9 .4 Μ耳 白 胺 酸 4 .3 8 .1 其耳 組 胺 酸 1 .8 «w 3 .8 其耳 絡 胺 酸 1 .7 3 .3 其耳 離 按 酸 6 .0 11 .2 莫耳 異 白 胺 酸 3 .1 5 .9 契耳 麩 胺 酸 2 .2 4 .2 契耳 精 胺 酸 2 .4 «&quot;w 4.6 Μ耳 苯 丙 胺 酸 2 .6 5.0 契耳 酪 胺 酸 4 .2 7 .8 契耳 色 胺 酸 1 .5 --S-· 2 .9 莫耳 本 發 明 亦 保 有 關 於 製 造 具 有 補 充 因激烈 蓮 動 所 引 起 之 血 液 中 減 少 之 胺 基 酸 t 提 升 浬 動 機 機 和減輕 運 動 疲 勞 1 以 及 具 有 恢 愎 疲 效 果 之 胺 基 酸 組 成 物 用 途之HV A A Μ之使用方 法 ; 製 造 具 有 補 充 伴 因 激 烈 運 動 所 引 起之血 液 中 減 少 之 胺 基 酸 * 提 升 運 動 機 能 和 m 輕 埋 動 後 之 疲勞以 及 恢 復 疲 勞 效 果 之 胺 基 酸 組 成 物 用 途 之 V Λ AM之 使 用 方法; 裂 造 具 有 抑 制 血 液 中 胺 基 酸 濃 度 费 動 並 提 高 其 保 持 力之胺 基 m 組 成 物 用 途 之 Η V ΑΑΜ之使用方法; 以及製迪具有抑制血液中胺基酸 濃 度 變 動 並 提 高 其 保 持 力 之 胺 基 酸 Μ 成物用 — 途 之 V A AM 之 使 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度通用中國圉家標隼(CNS ) Λ4规格(2]〇X297公釐) 3 8 6 3 5 413633 A7 B7 五、發明説明(5 ) 用方法。 圖而:&gt; 簡罝锐明 第1圖示(A)VAAM的胺基酸組成(契耳《 )與(B)運動後 疲勞時血液中胺基酸之減少量(μ莫耳/公升)之間的相閘 關像。 第2圖示第1圖中所示因運動疲勞而引起之血液中胺 基酸之減少率(¾ )與VAAM中胺基酸含量(莫耳% )之間的相 關閛。圖中號碼僳依據VAAM中胺基酸含貴之高低順序由高 而低表示者。星形記號示胺基酸中其滅少量顯示有意 差異者。 第3圖乃游泳前的_鼠先投與本發明之組成物(H VAAM 或VAAM),游泳後潮定鼸鼠血中乳酸值(平均值)並以圃示 者。圖中垂直線段示標準誤差值。 第4圖乃游泳前之SS®投與本發明之組成物(HVAAM或 V A A Μ ),游泳後再測定诱鼠之血糖(蒱萄糖)值(平均值)並 以圖示者。圖中垂直線段示檫準誤差值。 第5圖乃游泳前之鼷鼠先投與本發明之組成物( 經濟部中央標隼局:^工消費合作社印狀 (请先閱讀背面之注意事項再填寫本頁) HVAAM或VAAH),游泳後再測定鼴鼠之血液中游離脂肪酸值 (平均值)並以圖示者。圖中垂直線段示撩準誤差值。 第6圖示游泳前之譎鼠分別投與本發明之組成物( Η V A A M ), C Λ A Μ 萄糖或蒸餾水,並於游泳後再測定鼸鼠 血液中缠胺基酸濃度之減少情形者。 第7圖示游泳前之鼴鼠分別投與本發明之組成物( Η V A A M ), C Λ Λ Μ ,葡萄糖或蒸豳水,並於游泳後再測定鼸鼠 本紙伕尺度適用中國國家標準(CNS ) Λ4規格(210Χ 297公釐) 7 3 8 6 3 5 413633 A7 B7 五、發明説明(6 ) 血液中各胺基酸蘐度之變化情形者。 第8圖示分別投與本發明之組成物(VAAH), CAAH,或 蒸蹓水給家鼠,再分成運動一定時間群(a)和非蓮動群(b) ,然後分別測定家鼠之血液中葡萄糖濃度(平均值)之經時 變化曲線。圖中之垂直線段示標準誤差值3 第9圃示對家鼠分別投與本發明之組成物(VAAM). C A A Μ ,或蒸皤水.再分成蓮動一定時間群(a )和非運動群( b),然後分別测定家鼠血液中乳酸港度(平均值)之經時變 化曲線。圖中之垂直線段示捸準誤差值。 第10圈示對家鼠分別投與本發明之組成物(VAAM), CAAM或蒸皤水,再分成連動一定時間群(a)和非運勛群(b) ,然後分別測定家鼠血液中非酯化脂肪酸濃度(平均值)之 經時變化曲線,圖中之垂直線段示操準誤差值。 經濟部中央樣华局實工消费合作社印製 (請先閱讀背面之注意事項再填坏本頁) 第11圖示對家E分別投與本發明之組成物(VAAH), CAAM或蒸皤水,再測定運動一定時間群的家鼠血液中之胺 基酸濃度的變化。黑線筷示VAAM投與群,斜線條示CAAH投 與群,白線蝾示蒸餾水投與群之家鼠血液中之各胺基酸璣 度。U)示投與前,(b)示投與30分鏡(抱步0分鐘),(c) 示咆步45分鐘後,(d)示咆步90分鐘後之血液中的胺基酸 組成。星形記號者示和V Λ Λ Η投與群比較结果顯示有意差異 (ρ&lt;0 . 05 )者。(Inhibits the change of amino acid composition in the blood and improves its retention effect) This test is to use domestic rats as experimental animals to prove that the administration of VAAM before exercise can inhibit the decrease of the degree of S acid in the blood during exercise. Domestic rats (Sprague Dawley rats, males, 6 years old, 3 per group, average weight 190g) were used as experimental animals. After fasting overnight, the table shown in Table 2 was changed from 64 », 04 丨" &lt; ( The tyrosine amino acid mixture) is prepared into an aqueous solution of 3.8 wt.% Or steamed with "water 0.4 · 丨 and administered orally, and then rested at room rent for 30 minutes. Followed by a 7 ° motor driving the lotus lotus device (23 cm per minute) for 90 minutes. Blood samples were taken 30 minutes before the show, at the beginning of Baobu, at the 45th minute of Liaobu, and at 90 minutes after the hug, to determine their lactic acid, glucose, and non-esterified fatty acid (KEFA) concentrations. The non-holding group except the non-holding group is completely treated in the same way and performs the same analysis. The results are shown in the 8th round to the 12th round. The eighth to tenth figures show the effects of VAAM, CAAM, or steamed water on the blood glucose level of glucosamine, blood lactic acid, and the concentration of non-esterified fatty acids in blood. On the eighth to tenth laps, U) shows the step group and (b) shows the non-step group. The star character St indicates that the comparison of the VAAM voting group shows the result of an intentional difference (P &lt; 0.05). From the eighth nursery, <a), it can be seen that the concentration of inulin in the blood was slightly off when the group was administered with CAAM or steamed water, but it showed a significant decrease after 45 minutes and 90 minutes. Relatively speaking, the VAAH investment group did not decrease with 45 minutes of shovel. After 90 minutes of shovel, compared with other investment groups, the VAAH group showed intentional difference (p &lt; 0.05). The blood paper size of the non-holding group [No. 8 (b)] uses the Chinese Standard (CNS) A4 (210X297 mm) 20 {correction page) 38635 (Please read the notes on the back before filling This page} For example, printed by 633 Μ Β7 Printed by the Consumers' Cooperative of the Central Standard Bureau of the Ministry of Economic Affairs. 5. Description of the invention (1) The present invention is related to the amines in saliva 1 1 I secreted by the larvae of Vespa 腾The amino acid composition obtained from the information on the composition of amino acids is described in detail 1 1 »The present invention relates to blood supplements caused by intense exercise 1 I Please reduce the amino acids in the ribs to enhance exercise The amino acid composition 1 that can relieve fatigue and fatigue after exercise, and rehydration fluid containing 1 t of the composition on the back of the composition 0 meaning l thing 1 is rare in the past The research report of the vespa larva 1 The study report of saliva secreted by the vespa larva 1 1 is almost non-existent. The composition of the saliva is not completely nested {Ben 'l · c 1 The details are astonishing and m is amazing What is the nutritional endurance of the lotus's dynamic endurance? Page 1! The percentages contributed are even less clear about C i I The researchers of the present invention are engaged in the study of saliva secreted by various wasps larva »1 1 Explain the composition of saliva and find the composition Can effectively regulate the metabolism of lipid n 1 \ sugars and explain the active ingredient 0 It has now been found that when taking the amino acid nutritional solution secreted by wasps larvae in J 1 1 q mode, it has m section lotus 1 I Metabolism of lipids and carbohydrates during movement (refer to Japanese patent, for example, Kaikai Hei 11 (% 3-128318 Publication 1 To be Kaikai Hei 4-9 5 0 2 6), Ping 4-\! 1 1 2 8 2 5 ¾ Gazette ψ JP 4 ~ 1 2 0 0 2 0) 0 1 i The researchers of the present invention have shown that the wasp nutrient solution can inhibit fatigue during exercise 1 1 Substance production 1 SJ prevents the drop of blood glucose level * It can help to improve exercise capacity 1 l 0 The above mechanism of action shows that it can promote the use of fat as exercise 1 1 energy caused by vespidine as the main component of this nutrient solution The mixture i \ 1 (V es pa in i no acid mi X ture, abbreviated as VAA Μ) has been known to have various other effects besides the above-mentioned 1 I 1 use, as well as the function of restoring fatigue caused by exercise 1 1 fruit 0 Fatigue caused by exercise is known to cause amines in the blood. Significantly 1 1 This paper size applies the Chinese National Standard (CMS) Λ4 grid (210X297 mm) 3 3 8 8 3 5 413633 B7 Central Ministry of Economic Affairs 榡Printed by the quasi-bureaucracy co-operative cooperatives V. · Description of the invention (2) 1 Loss of the original balance 0 Anthrax species is considered to be the result of wear and damage caused by the adversity of the body group 1 1 | Adversity (S t Γ es S) that comes with exercise. 1 1 I Until now r Few people pay attention to its physiological significance and importance. 0 1 I The researchers of the present invention are asked to study the amino acid composition in the blood after exercise and the waspamine first M 1 AS 1 I amino acid mixture. Result 1 It was found that the amino acid composition of VAAH 1¾ 1 t 1 is very important to pay attention to the reduction of amino acids in the blood caused by the fatigue of lotus root [I thing 1 lang m% 〇 In other words »due to fatigue The more the amino acid is destroyed, the less 9 it is, and then the 1 is filled. The more the content of VA Α Η Φ is, the more 0 is written. Page 1 For the improvement of exercise function and recovery of fatigue 1 The above-mentioned reduction of amine groups and ~-ί acid supplement rrftr is an indispensable method — 0 Therefore f the inventors and others are 1 1 The reduction of the amino acids in the blood during fatigue and the 1 1 amino acid composition in the VA AM has been made with the discovery of the fact that the amino acid composition has a very high correlation with m%-a step by step research 1 Therefore, the cost of the invention is one hundred percent. Of providing — a kind of amino acid composition ψ 恃 Do not be a fluid containing 1 1 amino acid composition 〇 The amino acid composition or fluid replacement can be supplemented 1 1 (amino acids in blood produced with accompanying exercise Destroyer i has the effect of improving exercise machine \ 1 can reduce exercise fatigue and post-recovery fatigue, etc. 0 1 1 Another huge feature of the present invention is that it can suppress m to 1 1 blood accompanied by intense exercise. Method i for changing the amino acid concentration in the medium and improving its maintenance i and the method 1. The amino acid composition used in the method must be a rehydration solution 0 1 containing the amino acid M product 1 | The amino acid composition (hereinafter Ί = or HVA AM for short) contains 1 1 I amino acids with the following Kiel ratio * 1 1 晡 amino acid 12. 6 2 3. 4 Mohr 1 1 This paper is applicable to the standard 囷National Standard Soap (CNS) Λ4 Specification (2! 0X 297 mm) 413633 A7 B7 Printed by the Consumers ’Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the Invention (3) II Alanine 8.4 ~ 15.6 Μ Ear 1 1 I Glycine 13, 3 ~ 24.9 MU Ear 1 1 1 Valine 8 &gt; 2 ~ 15.4 MU Ear 1 1 Please 1 I Threonine 5.0 0 ~ 9.4 MU Ear M Ί 1 | Leucine 4, 3 ~ 8.1 Hipamine 1 1, 8 ~ 11.9 Moer Attention Jing 1 | Serine 1,7 ~ 3,3 Its ear item is again 1 1 Amino acid 6 -0 ~ 11.2 Wu Er tower (Ben t-page 1 Isoleucine 3] ~ 5.9 Gels f Amino acid 2 • 2 ~ 10.4 MU Ears 1 1 Arginine 2, 4 ~ 4.6 Gels 1! Phenylalanine 2 • 6 ~ 5,0 Μ Fertilizers i Tyrosine 4. 2 ~ 7 , 8 Mol! 1 Tryptophan 1 • 5 ~ 2,9 MU 1 1 The present invention is also related to the administration of Η VAA Μ to lactating animals to provide inhibition with 1 1 (% amine in blood caused by exercise The method for changing the concentration of amino acids 0 1 The present invention further includes the amino acid composition of VA AM, or each amino acid composition 11 1 The amino acid composition whose ear bb ratio changes within a range of 30% plus or minus, among which 1! It is better to set the range of m to 20%, and mine is better to be within 10% of range. The present invention includes 1 1 0 for the present invention, which contains 1 I 1 according to the following amino acid ratios and provides 1 for suppressing fluctuations in the concentration of amino acids in blood caused by exercise | Amino m composition for use (Hereinafter referred to as 1, 1-amidophenol composition is 1 1 IV AAH), and 1% of the amino acid sleeve is administered to a mammal to hold it, and I 1 provides a mechanism for inhibiting accompanying exercise Method for causing changes in amino acid feed in blood C 1 1 This paper size applies Chinese National Standard (CNS) Λ4 specification (210X297 mm) 5 3 8 6 3 5 «3633 A7 B7 V. Description of the invention (Central Ministry of Economic Affairs) Proximate Bureau employee consumer cooperative prints proline 12.6 23 .4 certain alanine 4 .2 «V 7 .8 moleglycine 13.3 24 .9 chelvaline 4 .1 7 .7 Molethuronic acid 5.0 0 9.4 M Ear leucine 4 .3 8 .1 Its ear histidine 1.8 .w «w 3 .8 Its ear melamine 1 .7 3 .3 Its ear separation acid 6.0 11 .2 Moralesulinic acid 3. 1 5 .9 Chelic acid glutamic acid 2. .2 4 .2 Chelic acid arginine 2. .4 «& quot w 4.6 μM amphetamine 2 .6 5.0 Chel tyrosine 4 .2 7 .8 Chel tryptophan 1 .5 --S- · 2 .9 Mor Reduction of amino acids in blood caused by lotus movements. Use of HV AA Μ for boosting motor machinery and reducing exercise fatigue1, and for amino acid composition use with recovery effect; manufacture supplements with intense exercise Induced reduction of amino acids in blood * Use of V Λ AM for amino acid composition applications that enhance exercise performance and fatigue after light burial and restore fatigue effects; cracking has the ability to inhibit amino acids in blood Concentration exhausts and increases its retention How to use V ΑΑM for the use of amino m composition; and to make amino acid M products that have the ability to suppress the fluctuation of amino acid concentration in the blood and improve its holding power-the use of VA AM (Please read first Note on the back side, please fill in this page again) This paper is in accordance with the Chinese Standard (CNS) Λ4 specification (2) × 297 mm 3 8 6 3 5 413633 A7 B7 V. Description of the invention (5) Method of use. Figures: &gt; Jian Jianming Ming 1st graph (A) VAAM amino acid composition (Qieer ") and (B) amino acid reduction in blood after exercise fatigue (μmol / L) Phase gate close image. Figure 2 shows the correlation between the reduction rate of amino acids in blood (¾) due to exercise fatigue and the amino acid content (mol%) in VAAM. The number 僳 in the figure is represented by high and low according to the order of the amino acid content of VAAM. The star-shaped symbol shows that the amount of the amino acid in the amino acid shows an intentional difference. Figure 3 shows the composition of the present invention (H VAAM or VAAM) before swimming in the rat. After swimming, the lactic acid value (average value) in the blood of the mole rats is determined by the nursery. The vertical line in the figure shows the standard error value. Figure 4 shows the composition of the present invention (HVAAM or VA AM) administered to SS® before swimming, and the blood glucose (glucose) value (average value) of mice after swimming was measured and shown in the figure. The vertical line segment in the figure shows the value of the quasi-error. Figure 5 shows the mole before the swimming with the composition of the present invention (printed by the Central Bureau of Standards of the Ministry of Economic Affairs: ^ Industrial Consumer Cooperatives (please read the precautions on the back before filling in this page) HVAAM or VAAH), swimming Then the free fatty acid value (mean value) in the blood of the mole is measured and the figure is shown. The vertical line segment in the figure shows the value of the quasi-error. Figure 6 shows the mole rats before the swimming administration of the composition of the present invention (Η VAAM), C Λ A Μ glucose or distilled water, and the reduction of the amino acid concentration in the blood of the mole is measured after swimming. . Fig. 7 shows the mole before swimming. The composition of the invention (Η VAAM), C Λ Λ Μ, glucose or steamed water were respectively administered, and the size of the mole paper was measured after swimming. The Chinese national standard (CNS) ) Λ4 specification (210 × 297 mm) 7 3 8 6 3 5 413633 A7 B7 V. Description of the invention (6) Changes in the degree of each amino acid in the blood. The eighth figure shows that the composition of the present invention (VAAH), CAAH, or steamed water is administered to house rats, and then divided into a certain exercise group (a) and a non- lotus group (b). Curve of glucose concentration (average value) in blood over time. The vertical line in the figure shows the standard error value 3. The ninth plot shows that the composition of the present invention (VAAM), CAA M, or steamed water is administered to domestic rats, and is divided into a certain time group (a) and non-movement. Group (b), and then measured the time-varying curve of lactate port (average value) in the blood of house rats. The vertical line in the figure shows the value of the quasi-error. Circle 10 shows that the composition of the present invention (VAAM), CAAM or distilled water is administered to domestic mice, and then divided into a group (a) and a non-union group (b) for a certain period of time. The curve of non-esterified fatty acid concentration (average value) over time. The vertical line in the figure shows the alignment error value. Printed by the Central China Bureau of the Ministry of Economic Affairs and the Consumer Cooperatives (please read the precautions on the back before filling out this page). Figure 11 shows that the household E separately administers the composition (VAAH), CAAM or distilled water of the present invention. Then, the changes of the amino acid concentration in the blood of domestic rats of a certain period of exercise were measured. The black line chopsticks show the VAAM administration group, the oblique line shows the CAAH administration group, and the white line shows the distilled water administration to the amino acid levels in the blood of the house mice. U) Before the administration, (b) The 30 minutes (0 minutes), (c) After 45 minutes, (d) The amino acid composition in the blood after 90 minutes . The star-shaped symbol indicates that the comparison result of V Λ Λ Η cast and group shows an intentional difference (ρ &lt; 0.05).

第1 2圖示分別以本發明之組成物(V A A M ), C A A Μ或猱脯 水投與家E,再測定未運動一定時間群之家鼠血液中按基 醉濃度之變化曲線。黑線條示VAAH投與群,斜線條示CAAM 本紙悵尺度適中國國家標準(CNS ) A4現格(210X297公釐) 8 3 8 6 3 5 413633 A7 B7 經濟部中央標準局員工消赍合作社印^ 五、 發明説明(7 ) 1 投 與 群 白 線 條 示 蒸 Afit 脚 水 投 與 群 之 家鼠血液 中之 各胺基酸 1 1 濃 度 〇 (a )示投與前, ( b) 示 投 與 30分鐘後, (c)示投與75 1 1 分 鐘 後 &gt; 以 及 (d)示投與1 20 分 鐘 後 之血液中 胺基 酸Μ成。 1 I 請 1 I 星 形 符 號 者 俱 表 示 和 投 與 V AAM 群 bh 較結果顯 示有 意差異( 先 閱 讀 I r P&lt; 0 . 05 )者。 背 面 1 ! 之 實 施 本 發 明 之 最 佳 方 法 如 下 0 注 意 ! 1 本 發 明 的 較 佳 胺 基 酸 組 成 物 (Η VAAH) 含有下列莫耳比 項 具 I 填 I 率 的 胺 基 酸 : ^ ( 本V 士 頁 1 m 胺 酸 14 .4 21 .6 Μ 耳 s_^· i 丙 胺 酸 9 .6 14 .4莫 耳 1 1 甘 胺 酸 15 .2 23 .0 Μ 耳 ! 1 绨 胺 酸 9 .4 14 .2莫 耳 訂 l 蘇 胺 酸 5 .8 8 • 7 Μ 耳 ] I 白 胺 酸 5 .0 7 .5 Μ 耳 1 1 1 組 胺 酸 2 .0 11 • 0 Η 耳 1 1 / 4泉 絲 胺 酸 2 .0 3 .0 Μ 耳 I 1 離 胺 酸 6 .8 &quot;S-· 10 .4其 耳 1 1 異 白 胺 酸 3 .6 5 .4莫 耳 1 1 麩 胺 酸 2 .5 &lt;~s_» 9 .6 Μ 耳 i i 精 胺 酸 2 .8 4 .2 Μ 耳 1 I 苯 丙 胺 酸 3 .0 »-«w 4 .6 Μ 耳 I 1 I 酪 胺 酸 4 .8 7 .2 Μ 耳 1 i 色 胺 酸 1 .7 2 .7轉 耳 1 I 本 發 明 的 最 佳 胺 基 酸 組 成 物 (Η V Λ ή Μ ) 含 有下 列契耳比 1 1 本紙浪尺度適用中1國家標準(CNS ) Λ4規格(2ί〇Χ 297公釐) g 3 8 6 3 5 413633 A7 Β 明説 明發的 、 率五 酸 : 胺 酸脯 基 胺 酸 酸酸酸 酸酸酸 胺胺胺按胺胺胺 丙甘 纈蘇 白組络 -------- 耳耳 耳耳耳 耳耳耳 莫莫莫《 莫莫契Μ (請先Μ讀背面之注意事項再填寫本頁) 離 胺 酸 7 . ,7〜 9 . 5 其 耳 異 白 胺 酸 4 . ,0〜 5 . 0 契 耳 麩 胺 m 2 . .8〜 8 . 8 契 耳 精 胺 酸 3 . ,1〜 3 . 9 莫 耳 苯 丙 胺 酸 3 , ,4〜 4 . 2 Μ 耳 酪 胺 酸 5 . .4〜 6 . 6 其 耳 色 胺 酸 1 .9〜 2 . 5 Η 耳 本發明之組成物(HVAAM)中,組胺酸之契耳比率以6. 4 〜U. 9莫耳為宜,其中以7.2〜11.0契耳為較佳.最佳為 8.1〜10.1莫耳。S外,麩胺酸之莫耳比率以5,6〜10.4為 宜,其中以6. 4〜9 .6萬耳為較佳,最佳為7.2〜8. 3莫耳。 本發明之胺基酸Μ成物中所使用之胺基酸以L -胺基酸 為最佳。本發明之胺基酸組成物中除上述胺基酸外,尚可 含甲硫胺酸(以0.3〜0.7莫耳%為宜,其中以〇,4〜0.6莫 耳%為較宜),天冬胺酸(以〇 · 1〜〇 . 3 Μ耳%為宜),牛磺 本紙張尺度適川中國國家標準(CNS ) Λ4規格(210X 297公釐) Γ〇 3 8 6 3 5 A7 B7 經濟部中央橾隼局負工消費合作社印狀 五、發明説曰/ ( 9 ) ! 酸 (以3 其耳%以下為宜), 酸 乙 醇 胺 (以2 莫耳 «以下 [ 1 為 宜 ), 胱胺酸(以 0 · 5莫耳 «以下為宜) t 0 -丙胺酸&lt; 以 1 1 1 莫 耳 % 以 下 為 宜 ), y - 胺 基 丁 酸 (以0 .5 莫 耳 % 以 下 為 宜 ), 1 I 請 1 鳥 胺 酸 (0 r η i t hi n e )或乙酵胺(以 3 莫 耳 % 以 下 為 宜 ), 氛( 聞 讀 1 | 以 2 莫 耳 % 以 下 為 宜 ), \ -甲基組胺酸(以 3 Μ 耳 % 以 下 為 背 I 之 宜 )’ 3 -甲基組胺酸(以 1 Μ 耳 % 以 下 為 宜 )0 注 0: 1 1 m 造 本 發 明 之 胺 基 酸 組 成 物 時 t 只 要 按 眧 上 述 所 定 tb 項 i i 填 1 率 混 合 市 販 之 上 述 胺 基 m 即 可 C 又 製 成 補 液 使 用 時 以 m m %i 本、 水 溶 解 上 述 胺 基 酸 組 成 物 即 可 Λ 一 般 以 粉 末 狀 混 合 均 勻 做 頁 1 ί 成 組 成 物 t 使 用 時 利 用 m m cm 水 溶 解 即 可 0 關 於 本 發 明 組 成 1 1 物 之 製 造 保 存 溫 度 並 無 特 別 限 制 1 但 通 常 以 室 溫 以 T 溫 1 1 度 製 造 % 保 存 為 宜 0 本 發 明 之 組 成 物 呈 現 徹 弱 苦 味 t 經 Π 訂 i 投 與 m 鼠 時 1 使 用 至 20g/ kg 量 也 完 全 未 發 現 有 骞 性 % 可 知 I 其 L0 5〇 遠 超 過 20 ε / k g 以 上 值 C 1 1 | 本 發 明 之 組 成 物 可 提 供 翳 m 或 飲 料 等 食 C3 ΡΠ 方 面 有 益 用 1 ! / 線 途 0 提 供 m 用 途 時 其 投 與 方 法 並 無 待 別 限 制 , 可 利 用 \ I 經 □ 投 與 参 直 m 投 與 1 注 射 » 輸 液 投 與 等 般 常 見 投 與 方 1 1 法 0 經 □ 投 與 時 t 可 將 含 有 上 述 組 成 之 組 成 物 • 必 要 時 利 I I 用 路 m 上 容 許 使 用 的 載 剤 賦 形 劑 等 科 成 錠 剤 t m 囊 削 I 散 _ * Μ t 糖 漿 劑 等 製 劑 使 用 C 但 是 錠 劑 或 牧 m 等 固 態 1 I m 劑 之 吸 收 較 費 時 間 1 因 此 以 利 用 液 m 等 經 P 投 與 為 宜 1 1 1 C 經 P 投 時 可 利 用 適 當 添 加 物 I 例 如 氮 化 納 等 塩 類 * 缓 1 1 衝 劑 1 螯 合 劑 等 — 起 調 成 水 溶 液 後 投 與 為 宜 0 又 以 射 1 1 劑 利 用 時 , 可 添 加 適 當 的 緩 衝 劑 1 等 m m 等 用 殺 μ 餾 1 1 本紙張尺度適用中國國家標準(CNS &gt; Λ4ί見格(210X297公釐) ]1 3 8 6 3 5 A7 B7 五、發明説明() 水溶解後採用例如點滴方式注人舯脈内為宜。 提供食品用途時,可增加適當風味調製為飲料,例如 淸涼飲料或粉末飲料使用,或例如使用噴菘乾燥法.谏結 乾燥法,撇細粉末法等製成粉末後,再製劑成膠囊劑或錠 劑形態使用均宜。 本發明組成物鼷極低毒性.因此,其投與S範圍可設 定非常廣範。投與量視投與方法,使用目的而異,通常按 照組成物之固形物計,一次投與1〜12g,每日投與fi在3 〜13g範圍,其中以一次投與2〜4g範圍,一日投與6〜12s 為宜。Figure 12 shows the composition of the present invention (V A A M), C A A M, or candied water, which was administered to House E, and then the curve of the concentration of basal adenosine in the blood of rats without exercising for a certain period of time was measured. The black line shows the VAAH investment group, the oblique line shows the CAAM paper size suitable for the Chinese National Standard (CNS) A4 (210X297 mm) 8 3 8 6 3 5 413633 A7 B7 printed by the staff of the Central Standards Bureau of the Ministry of Economic Affairs. V. Description of the invention (7) 1 administration group white line shows steamed Afit foot water administration group each amino acid in blood of group house mouse 1 1 concentration 0 (a) shows before administration, (b) shows administration 30 Minutes later, (c) shows that 75 minutes after administration of 11 minutes &gt; and (d) shows that the amino acid M in blood is taken after 120 minutes of administration. 1 I Please 1 I The star symbol indicates and applies to the V AAM group bh. The results show an intentional difference (read I r P &lt; 0.05). On the back side 1! The best method for implementing the present invention is as follows. 0 Note! 1 The preferred amino acid composition (Η VAAH) of the present invention contains the following molar ratios of amino acids with a filling ratio: ^ (本 V 1 m Amino acid 14.4 21 .6 M ears_ ^ · i Alanine 9 .6 14 .4 Mol 1 1 Glycine 15. 2 23 .0 M Ear! 1 Amino acid 9. 4 14 .2 Molten l Threonine 5. 8 8 • 7 MU Ear] I Leucine 5.0 .7 7 .5 MU Ear 1 1 1 Histamine 2.0 .11 11 • 0 耳 Ear 1 1/4 spring silk Amino acid 2. 0 3 .0 M Ear I 1 Leucine 6. 8 &quot; S- · 10 .4 Its ear 1 1 Isoleucine 3. 6 5. 4 Mole 1 1 Gluten acid 2.5 &lt; ~ s_ »9 .6 M ear ii Arginine 2. 8 4. 2 M Ear 1 I Phenylalanine 3.0.»-«w 4 .6 M Ear I 1 I Tyrosine 4 .8 7 .2 Mear 1 i Tryptophan 1. 7 2 .7 Rotate 1 I The best amino acid composition of the present invention (V Λή Μ) contains the following dear ratio 1 1 The paper scale is applicable to China National Standard (CNS) Λ4 specification (2ί〇 × 297 mm) g 3 8 6 3 5 413633 A7 Β, clearly stated, the rate of penta-acid: amine acid proline amino acid acid acid acid Amine amines amine amine propyl valerium white group -------- ear ear ear ear ear ear ear ear momomo Momomomo (please read the notes on the back before filling (This page) Lysine 7., 7 ~ 9. 5 Its leucoleucine 4., 0 ~ 5. 0 Chelteramine m 2.. 8 ~ 8.8 Chelteramine 3, 1, 1 ~ 3.9 Molar phenylalanine 3, 4, 4 ~ 4.2 M Ear tyrosine 5. 4 ~ 6.6 Its ear tryptophan 1.9 ~ 2.5 The composition of the present invention (HVAAM ), The ear ratio of histidine is preferably 6.4 ~ U. 9 moles, of which 7.2 ~ 11.0 Qi ear is more preferred. The most preferred is 8.1 ~ 10.1 mole. Besides S, the molar ratio of glutamic acid is preferably 5,6 to 10.4, of which 6.4 to 96,000 ears is more preferable, and the most preferable is 7.2 to 8.3 moles. The amino acid used in the amino acid M product of the present invention is preferably L-amino acid. In addition to the above-mentioned amino acids, the amino acid composition of the present invention may also contain methionine (preferably 0.3 to 0.7 mole%, and more preferably 0.4 to 0.6 mole%). Aspartic acid (preferably from 0.1 to 0.3 mol%), Taurine paper is suitable for Sichuan National Standard (CNS) Λ4 specification (210X 297 mm) Γ〇3 8 6 3 5 A7 B7 Economy Ministry of Economic Affairs of the Ministry of Work, Consumer Cooperatives, Seal 5. Fifth, invention said / (9)! Acid (preferably less than 3% of its ear), acid ethanolamine (to 2 moles «below [1 is appropriate), cystamine Acid (preferably 0.5 mol or less) t 0 -alanine &lt; preferably 1 1 1 mol% or less), y-aminobutyric acid (preferably 0.5 mol or less) , 1 I please 1 ornithine (0 r η it hi ne) or acetaminophen (preferably less than 3 mole%), atmosphere (read 1 | preferably less than 2 mole%), \-甲Base histidine (preferably less than 3 MW% as back I) '3 -methylhistidine ( 1 mol% is preferred) 0 Note 0: 1 1 m When the amino acid composition of the present invention is made, t can be made by mixing the above-mentioned amino group m in the market with 1 according to the above-mentioned tb item ii. When rehydration is used, the above amino acid composition can be dissolved in mm% i and water. Generally, it can be mixed evenly as a powder to make the composition. 1 Use t mm to dissolve in water. 0 About the composition of the present invention 1 1 There is no particular limitation on the storage temperature of the product 1 but it is usually made at room temperature and T temperature 1 1%. It is advisable to store 0. The composition of the present invention has a clear bitter taste. The amount of / kg is not found at all%. I know that its L0 50 is far more than 20 ε / kg or more. C 1 1 | The composition of the present invention can provide food such as 翳 m or beverages C3 ΡΠ useful 1! / Line route 0 There are no restrictions on the method of administration when m is provided. You can use \ I via □ to participate in direct m administration 1 to inject »common infusion administration methods such as infusion administration 1 1 method 0 via □ At the same time, the composition containing the above composition can be used. • If necessary, use the carrier excipients allowed on the road m, etc. into the tablets. Tm capsules I powder _ * Μ t syrups and other preparations use C but tablets The absorption of solid 1 I m agents such as or m is more time-consuming1 Therefore, it is advisable to use liquid m, etc. to be administered by P 1 1 1 C When P is administered, appropriate additives I, such as sodium nitride, etc., can be used. * 1 1 Granules 1 Chelating agents, etc. — It is advisable to adjust the solution to an aqueous solution. 0 and shot 1 1 when using, you can add an appropriate buffer 1 mm, etc. to kill μ distillation 1 1 This paper size applies Chinese national standards (CNS &gt; Λ4ί See grid (210X297 mm)] 1 3 8 6 3 5 A7 B7 V. Description of the invention () After the water is dissolved, it is advisable to inject it into the veins, for example, by dripping. When providing food use, you can add appropriate flavors to prepare beverages, such as cold drinks or powdered beverages, or use spray drying method, knot drying method, skimming powder method, etc. to make powders, and then formulate them into capsules. Or in the form of tablets. The composition of the present invention is extremely low in toxicity. Therefore, its S range can be set to a very wide range. The amount to be administered depends on the method of administration, and the purpose of use varies, usually based on the solids of the composition, 1 to 12 g at a time, and fi to 3 to 13 g per day, of which 2 to 4 g is administered at a time. It is advisable to administer it for 6 ~ 12s a day.

使用本發明組成物作為運動前、運動中或.運動後之補 液用途時,可調製成0.8〜1.5重量%之溶液,每日用置 200〜500ml,分成1〜3次投與s以注射劑使用時,可調製 成0.8〜1.5重量%之溶液,每次投與1〇〇〜400ralf較好為 投與1 5 0〜3 0 0 n U 本發明锫下列試驗例和實施例更具體地沣細説明,但 本發明範圍不受其侷限不待赘述。 經濟部中央標準局•負工消費合作社印¾ (請先閱讀背面之注意事項再填莴本頁) 试驗例1 (以人進行蓮動试驗) 本試驗之目的在調査人在運動前後血液中胺基酸組成 之變化情形。 U)血液中胺基酸之定蛋 採取O.lral的血液做為檢驗材料,添加等鼉的過累 酸使蛋白變性,離心,採取5 〇 Μ之上澄液,添加1Μ丨胺基 ______ _一_ ____ 一 本紙張尺度適用中國國家標隼(CNS ) Λ4規格(210X 297公釐) ;J g 6 3 5 413633 A7 B7 五、發明説明(1 1 ) 酸分析用試料稀樺劑做為分析試料。使用日立胺基酸分析 儀835型以印滿三酮法(ninhydrU呈色法)分析之。 (2 )人體試驗 令被檢者在室溫(2 4 ΐ:)下.於7 0 % V 0 2 b a X (最大氣氣 攝取量之70¾)的負荷下咆步90分鐘,然後利用脚踏車型 運動設備連動90分鐘至疲勞為止。於運動前和運動後分別 採血並測定其血液中之胺基酸組成。結果示於表1中。 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印51 3 8 6 3 5 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X 297公釐) 413633 A7 B7 五、發明説明(12 ) 表1 經濟部中央標準局爲工消费合作社印製 胺基酸種類 胺基酸濃度(μ mo丨e/jn 蓮動前(A)運動後(B)減少量(A-8) 減少率(% ) [(A-B)/A]x 100 晡胺酸 160.70 丙胺酸= 309.50 222.50 87.00 28.11 甘胺酸= 206.20 140.20 66.00 32.01 纈胺酸= 214.50 150.00 64.50 30.07 蘇胺酸Μ 134.70 106.10 24.60 18.82 白胺酸= 114.00 92.40 21.60 18.95 組胺酸W 62.40 42.00 20.40 32.70 絲胺酸^ 113.40 101.10 12.30 10.85 離胺酸 147.90 135.00 12.00 8.11 異白胺酸# 67.00 55.30 11.70 17.46 麩胺酸C 22.40 16.10 6.30 28.13 堉胺酸 63,80 57,80 6.00 9.40 甲硫胺酸 24.90 23.40 1.50 6.02 胱胺酸 43.70 43.10 0.60 1.37 天冬胺酸 2.80 4.30 -1. 50 -53.57 苯丙胺酸 45.60 48,60 -3.00 -6.58 酪胺酸 53.90 59.90 -6.00 -11.13 色胺酸 36.80 本紙悵尺度適用中國國家標準(CNS ) Λ4現格(2丨Ο'乂 297公釐) (請先閱讀背面之注意事項再填寫本頁 i訂 14 38635 413633 經濟部中央標嗥扃負工消费合作社印&quot; A7 B7五、發明説明(u) 随薄動而引拓之血液中胺某齡站成夕戀化楢形ξίανΑΑΜΦ粧 某醚站成:&gt; 卟I» 激烈蓮動至疲勞為止時,血液中胺基酸的變化情形可 分為顯著减少者,變化不大者,及稍為增加者等三種情形 。顯示有意差異(〇.05&lt;Ρ)之減少的胺基酸(表1中附以t;;區 別者)有丙胺酸,甘胺酸,纈胺酸,蘇胺酸,白胺酸,組 胺酸,絲胺酸,異白胺酸,麩胺酸等。另外,顯示有意差 異之增加的胺基酸為酪胺酸。不具有意差異而示增加的胺 基酸有苯丙按酸和天冬胺酸。同搛地,不具有意差異而示 減少的胺基酸為離胺酸,精胺酸,甲硫胺酸,胱胺酸和色 胺酸。其中.顯示有意差異之減少的胺基酸在VAAM的組成中 均以高含量存在(參考第1圖)。第1圖中,(Α)示VAAM之 胺基酸組成(莫耳% ), (8)示表1中所示運動後血液中胺 基酸之減少量U契耳/公升)。 此結果顯示VAAM對於運動用補充胺基酸組成物之有益性C 曹旃例1 本發明VAAM之胺基酸組成和随蓮動而引起之血液中胺 基酸減少率之相關關偽,以及根據該結果所調製之人用胺 基酸組成物(HVAAM)及其功能。 由第1圖中可知VAAM中的丙胺酹和纈胺酸含量[參考 第1圖U )項]較之人在運動後的桉基酸之減少里[參考第 1圖U)項]為低。另外,已知組胺酸或麩胺酸不顯示脂筲 誘導效果。考盧上述冏題之後,將運動後血液中的各胺基 本紙張尺度適用中圃®家標準(CNS Μ4规格(2ί〇χ297公釐) ! 5 3 8 6 3 5 (請先閲讀背面之注意事項再填筠本頁) 413633 A7 B7 經濟部中央標準局只工消費合作社印製 五、發明説明( 1 4 ) 1 酸 減 少 率 (« ) 針 對 V A A Μ中 所 含 胺 基 酸 的 含 有 莫 耳 bb 率 而 繪 ί 1 製 成 第 2 圖 0 由 第 2 rat 圖 可 知 t 蓮 動 後 血 液 中 胺 基 酸 之 減 少 1 1 率 (« ) 和 V A AH 中 所 含 胺 基 酸 之 Μ 耳 比 率 有 很 好 相 關 關 像 ( 1 I 請 1 I Γ = 0 . 8 4 )〇 該結果顯示V ΑΛ Μ在運動時對於人體之有益性。 先 閱 1 I 讀 I I 然 而 由 第 2 圖 也 可 知 丙 胺 酸 f 缴 胺 酸 * 組 按 酸 和 m 胺 酸 顯 背 1¾ 1 i 之 I 然 不 符 A CI 該 相 關 回 歸 直 線 而 大 大 減 少 0 因 此 t 配 合 該 相 關 注 意 1 I 關 而 增 加 胺 基 酸 量 所 調 製 的 胺 基 酸 组 成 物 理 應 較 V A AH 更 事 項 真 1 1 1 可 期 待 其 對 人 體 蓮 動 時 增 進 運 動 機 能 和 運 動 後 恢 復 疲 勞 的 太\ h 頁 i 優 異 效 果 〇 1 針 對 由 第 2 圖 所 示 相 關 直 線 所 期 待 之 減 少 率 而 * 組 1 1 胺 酸 顯 示 3 . 5倍, 麩胺酸示2 5倍 s 纈 胺 酸 和 丙 胺 酸 分 別 顯 1 1 示 2 倍 等 的 高 滅 少 率 0 因 此 » 在 VAAM 同 —* 組 成 的 胺 基 酸 組 訂 1 成 物 中 分 別 增 加 上 述 4 棰 胺 基 酸 量 而 成 為 本 發 明 之 胺 基 酸 ί I 組 成 物 0 ϊ 1 j 播 補 充 上 述 按 基 酸 &gt; 可 提 供 對 於 人 髏 之 增 進 運 動 機 能 1 1 ( Λ 或 恢 復 疲 勞 更 適 妥 的 胺 基 酸 組 成 物 0 該 胺 基 酸 組 成 物 ( 1 Η V A A M) 之 例 舉 之 一 示 於 表 2 中 (參考Η V A AM AP ) 〇 ί 1 另 外 * 組 胺 酸 和 麩 胺 酸 由 於 含 較 低 1 且 脂 肪 誘 導 效 I I 果 也 少 1 因 此 不 補 充 该 m 基 酸 Μ 目 的 之 效 果 也 不 會 降 低 1 l 〇 其 例 舉 之 一 合 併 示 於 表 2 (參考Η V A A Η B欄)〇 事 實 上 以 表 I 2 中 的 A 和 8 W 所 示 m 基 酸 組 成 物 之 1 , 5重置^ ;水溶液提 1 1 1 供 運 動 後 經 Π 投 與 3 0 0 m 1 ’ 即能顳箸改菩運動後之疲勞感 1 1 覺 或 肌 肉 痛 之 感 覺 0 1 1 1 1 16 本紙浪尺度適用中國國家標孳(CNS ) Λ4規格(2!ΟΧ297公釐) 3 8 6 3 5 413633 A7 B7 五、發明説明(i 5) 表2 胺基酸濃度(M耳比率) 胺基酸種類-When the composition of the present invention is used for rehydration before, during or after exercise, it can be adjusted to a solution of 0.8 to 1.5% by weight, 200 to 500 ml per day, divided into 1 to 3 administrations and used as injections. At the time, it can be adjusted to make a solution of 0.8 to 1.5% by weight, preferably 100 to 400 ralf each time, preferably 150 to 3 0 0 n U. The present invention, the following test examples and examples are more specific The description, but the scope of the present invention is not limited by them and need not be repeated. Printed by the Central Standards Bureau of the Ministry of Economic Affairs and Consumer Cooperatives ¾ (Please read the precautions on the back before filling out the lettuce page) Test Example 1 (Human lotus test) The purpose of this test is to investigate the blood of people before and after exercise Changes in amino acid composition in China. U) Amino acid in the blood: Take O.lral's blood as test material, add isocyanic acid to denature the protein, centrifugate, take 50 mM above solution, add 1 Μ amine group ______ _ 一 _ ____ One paper size is applicable to the Chinese National Standard (CNS) Λ4 specification (210X 297 mm); J g 6 3 5 413633 A7 B7 V. Description of the invention (1 1) Dilute birch agent for acid analysis Analyze the sample. It was analyzed using a Hitachi amino acid analyzer type 835 by the imprinting trione method (ninhydrU colorimetric method). (2) The human body test instructed the subject to walk at room temperature (2 4 2 :) for 90 minutes under a load of 70% V 0 2 ba X (70 ¾ of maximum air intake), and then use a pedal car Exercise equipment for 90 minutes until fatigue. Blood was collected before and after exercise, and the amino acid composition in the blood was measured. The results are shown in Table 1. (Please read the precautions on the back before filling this page) Printed by the Central Standards Bureau of the Ministry of Economic Affairs and Consumer Cooperatives 51 3 8 6 3 5 This paper size applies to China National Standard (CNS) A4 (210X 297 mm) 413633 A7 B7 V. Description of the invention (12) Table 1 The Central Bureau of Standards of the Ministry of Economic Affairs prints the amino acid types for the industrial and consumer cooperatives. The amino acid concentration (μ mo 丨 e / jn before lotus movement (A) after exercise (B) reduction ( A-8) Decrease rate (%) [(AB) / A] x 100 glutamic acid 160.70 alanine = 309.50 222.50 87.00 28.11 glycine = 206.20 140.20 66.00 32.01 valine = 214.50 150.00 64.50 30.07 threonine 134.70 106.10 24.60 18.82 Leucine = 114.00 92.40 21.60 18.95 Histamine W 62.40 42.00 20.40 32.70 Serine ^ 113.40 101.10 12.30 10.85 Leucine 147.90 135.00 12.00 8.11 Isoleucine # 67.00 55.30 11.70 17.46 Glutamic acid C 22.40 16.10 6.30 28.13 Amino acid 63,80 57,80 6.00 9.40 Methionine 24.90 23.40 1.50 6.02 Cystine 43.70 43.10 0.60 1.37 Aspartic acid 2.80 4.30 -1. 50 -53.57 Phenylalanine 45.60 48,60 -3.00 -6.58 Casein Amino acid 53.90 59.90 -6.00 -11.13 Tryptophan acid 36.80 The paper size of this paper is applicable to Chinese National Standard (CNS) Λ4 is present (2 丨 〇 '乂 297 mm) (Please read the notes on the back before filling in this page to order 14 38635 413633 Economy Printed by the Ministry of Standards and Consumers ’Cooperatives & Co., Ltd. &quot; A7 B7 V. Description of the invention (u) A certain age of amines in the blood that follows the thin movements has emerged as a xihuanhuahua shape ξίανΑΑΜΦ makeup of some ether: &gt; porphyry I »When the intense lotus movement to fatigue, the change of amino acids in the blood can be divided into three cases: significant decrease, small change, and slightly increase. It shows a reduction of intentional difference (0.05). The amino acids (with t in Table 1; the difference) are alanine, glycine, valine, threonine, leucine, histamine, serine, isoleucine, bran Amino acids, etc. In addition, an amino acid showing an increased intentional difference is tyrosine. Among the amino acids that do not have intentional differences but show an increase are phenylalanine and aspartic acid. Similarly, the reduced amino acids without intentional differences are lysine, arginine, methionine, cystine, and tryptophan. Among them, the reduced amino acids showing intentional differences are present in high content in the composition of VAAM (refer to Figure 1). In Fig. 1, (A) shows the amino acid composition (mol%) of VAAM, and (8) shows the reduction amount of amino acid in the blood after exercise shown in Table 1 (Uchiel / liter). This result shows the usefulness of VAAM for supplementing amino acid composition for exercise. C Cao Yu Example 1 The correlation between the amino acid composition of VAAM of the present invention and the rate of amino acid reduction in the blood caused by the movement of lotus, and according to the result Modified human amino acid composition (HVAAM) and its function. It can be seen from the first graph that the content of alanine and valine in VAAM [item U] in reference [1] is lower than that in the reduction of eucalyptic acid [refer to U. item 1 in post 1] after exercise. In addition, it is known that histidine or glutamic acid does not show the effect of inducing lipids. After the above questions, apply the basic paper size of each amine in the blood after exercise to the Zhongpu® Home Standard (CNS M4 specification (2ί〇χ297 mm)! 5 3 8 6 3 5 (Please read the precautions on the back first) (Refill this page) 413633 A7 B7 Printed by the Central Standards Bureau of the Ministry of Economic Affairs, and only printed by the Consumer Cooperative. V. Description of the invention (1 4) 1 Acid reduction rate («) Mole bb rate for amino acids contained in VAA M And draw 1 to make the second figure 0 From the second rat figure, we can see that the rate of reduction of amino acids in the blood after lotus root movement is 1 1 («) and the ratio of M ears of amino acids contained in VA AH is well correlated Close image (1 I Please 1 I Γ = 0.84). This result shows the beneficial effects of V ΑΛ Μ on the human body during exercise. Read 1 I Read II However, the second picture also shows that alanine f famine * The group according to the acid and m amino acid showed a back I of 1¾ 1 i, but it does not match the A CI. The correlation regression line is greatly reduced by 0, so t Cooperate with this related attention 1 I The amino acid composition adjusted by increasing the amount of amino acid should be more important than VA AH 1 1 1 It can be expected that it will improve the exercise performance of the human body during exercise and restore fatigue after exercise. \ h Page i Excellent effect 〇1 The reduction rate expected from the relevant straight line shown in Figure 2 * Group 1 1 amino acid shows 3.5 times, glutamic acid shows 2.5 times s Valine and alanine respectively It shows that 1 1 shows 2 times the high rate of elimination. Therefore, »the amino acid composition of VAAM with-* was added to the above 4 amino acid content to form the amino acid of the present invention. I The composition 0 ϊ 1 j broadcast supplementing the above-mentioned base acids &gt; can provide the human body with enhanced sports function 1 1 (Λ or amino acid composition more suitable for restoring fatigue 0 the An example of a basic acid composition (1 Η VAAM) is shown in Table 2 (refer to Η VA AM AP) 〇ί 1 In addition, histidine and glutamic acid have a lower content of 1 and a fat-inducing effect II. Less 1 The effect of not supplementing the m-based acid M will not decrease 1 l. One of the examples is combined and shown in Table 2 (refer to column Η VAA Η B). In fact, A and 8 in Table I 2 1 and 5 reset of m-based acid composition shown in W ^; 1 1 1 aqueous solution is provided for administering 3 0 0 m 1 after exercise, that is, the fatigue feeling after exercise can be changed 1 1 Feeling of pain 0 1 1 1 1 16 The scale of this paper is applicable to Chinese national standard (CNS) Λ4 specification (2! 〇 × 297 mm) 3 8 6 3 5 413633 A7 B7 V. Description of the invention (i 5) Table 2 Amino acid Concentration (M Ear Ratio) Amino Acid Type-

V AAM HVAAMA HVAAMB C A AM 脯 胺 酸 18 • 00 1 8 • 00 1 8 .00 8 • 50 丙 胺 酸 6 . ,00 1 2 .00 1 2 .00 4 .50 甘 m 酸 19 . .10 1 9 ‘10 1 9 • 10 4 .50 缬 胺 酸 5 . .90 1 1 .80 1 1 .80 5 . .50 蘇 胺 酸 7 . .20 7 .20 7 . .20 2 , .50 白 胺 酸 6 . .20 6 .20 6 . .20 8 . 50 組 胺 酸 2 . .60 9 .10 2 . .60 2 , ,50 絲 胺 酸 2 . ,50 2 ‘50 2 . .50 8 . ,00 _ 胺 酸 8 . .60 8 , .60 8 . .60 7 , ,00 異 白 胺 酸 4 . ,50 4 ' ,50 4 . .50 5 . ,50 麩 胺 酸 3 . .2 0 8 , ‘00 3 . .20 19 . ‘60 精 胺 酸 3 . '50 3 .50 3 . '50 3 · 00 甲 硫 胺 m 0 . 5 0 0 , 50 0 , .50 2 . .50 天 冬 胺 酸 0 . 2 0 0 , ,20 0 . .20 7 . 5 0 苯 丙 胺 酸 3 . 80 3 . ,80 3 , .8 0 4 . 00 酪 胺 酸 6 . 00 6 . 00 6 . 00 5 . 00 色 胺 酸 2 . 20 2 . ,20 2 . 20 1 . 00 胱 胺 酸 0 _ 4 0 本紙悵尺度通用中國國家標辛 ( CNS ) Λ4規格(2丨0X 297公釐) 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填辉本頁) 3 8 6 3 5 413633 A7 B7 五、發明説明(16) 本發明之組成物中各胺基酸之契耳比率以表2中所示 各胺基酸之契耳比率再加滅30¾為宜,其中以加減20¾為 較宜,最佳為加减10¾即可適用於本發明用途。 (持久蓮動時減輕運動負載之功能) 本試驗乃藉鼷鼠為試驗動物,運動前投與本發明之組 成物(HVAAM)證實可減輕持久蓮動時之蓮勘負載的效果。 本試驗按照文獻所記載方法進行(參考日本J. Phys. Fitness Sports Med. 1995. 44:225-238頁亦即,使 鼷鼠(雄鼠,ddy, 5遇龄)每群10隻在室溫下禁食16小時 後,以表2中所示組成物VAAM和HVAAMB調製成的1.8重量 «水溶液按照37.5μ1“腥重進行經口投與,鈒之在室溫下 休息30分鐘。然後今之在流水池(直徑32ca,深度30c·之 圓简型水槽,保持35t水溫,藉循琿設備造成每分鐘8公 尺之水流)中游泳30分鐘。然後測定游泳後誘E血中之乳 酸值、血糖(M萄糖)值和血液中游離脂肪酸值。其结果分 別示於第3圖、第4鼸及第5圖。 經濟部中央慄隼局員工消f合作社印製 (請先閱讀背面之注意事項再填寫本頁) 由第3圔可知較之投與V A A Μ群,Η V Λ A Μ B投與群在3 0分 鐘之負載游泳後,其血液中乳酸值較低,相貶地.第4圃 及第5圖卩lj分別顙示其血糖值及血液中游離脂肪酸值皆以 HVAAMB投與群顯示有意輓的較高值。由上述結果表示 HVAAM較之νΛΑΜ更能減輕伴随浬動而引起之運動負載。 试驗例3 (抑制血液中胺基酸組成之變化並提升其保持效果) 本纸乐尺度通用令國國家標準(CNS ) Λ4規格(210/297公釐) 18 3 8 6 3 5 413633 A7 B7 五、發明説明(1 7 ) 本試驗乃藉鼸鼠為试驗動物證實在運動前投與HVAAM 能抑制運動時血液中胺基酸濃度之降低。 本試驗乃按照文獻所記載方法進行(參考曰本J.V AAM HVAAMA HVAAMB CA AM Proline 18 • 00 1 8 • 00 1 8 .00 8 • 50 Alanine 6. .00 1 2 .00 1 2 .00 4 .50 Glycine 19. .10 1 9 ' 10 1 9 • 10 4 .50 Valine 5.. 90 1 1 .80 1 1 .80 5. .50 Threonine 7. .20 7 .20 7. .20 2, .50 Leucine 6. .20 6 .20 6. .20 8. 50 Histamine 2. .60 9 .10 2. .60 2,, 50 Serine 2., 50 2 '50 2. .50 8., 00_amine Acid 8.. 60 8,. 60 8.. 60 7, 00 Isoleucine 4., 50 4 ', 50 4.. 50 5. 50 Glutamic acid 3.. 2 0 8, '00 3 .20 19. '60 Arginine 3. '50 3 .50 3. '50 3 · 00 Methionine m 0. 5 0 0, 50 0, .50 2. .50 Aspartic acid 0.2 0 0,, 20 0.. 20 7.. 5 0 Alanine 3. 80 3., 80 3,. 8 0 4. 00 Tyrosine 6. 00 6. 00 6. 00 5. 00 Tryptophan 2. 20 2., 20 2. 20 1. 00 Cysteine 0 _ 4 0 The standard of this paper is common Chinese National Standard Xin (CNS) Λ4 specification (2 丨 0X 297 mm) Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (Please read the notes on the back before filling this page) 3 8 6 3 5 413633 A7 B7 V. Description of the invention (16) The ratios of the amino acids in the composition of the present invention are shown in Table 2. It is better to add 30 ¾ of the amino acid chelate ratio, in which 20 ¾ is more preferable, and 10 ¾ is most suitable for the application of the present invention. (Function of Reducing Exercise Load During Permanent Lotus Movement) This test was conducted by using moles as test animals, and it was confirmed that the composition of the present invention (HVAAM) before exercise could reduce the effect of reducing lotus load during persistent lotus movement. This test was performed in accordance with the method described in the literature (refer to Japanese J. Phys. Fitness Sports Med. 1995. 44: 225-238). That is, 10 rats per group (male, ddy, 5 at age) were kept at room temperature. After fasting for 16 hours, a 1.8-weight «water solution prepared with the compositions VAAM and HVAAMB shown in Table 2 was orally administered at a weight of 37.5 µ1", and left to rest for 30 minutes at room temperature. Then this time Swim for 30 minutes in a flowing pool (a circular simple sink with a diameter of 32ca and a depth of 30c ·, maintaining a water temperature of 35t, and using a loop device to create a water flow of 8 meters per minute). Then measure the lactic acid value in the E blood after swimming , Blood glucose (M-glucose) value and free fatty acid value in the blood. The results are shown in Figure 3, Figure 4 and Figure 5. Printed by the Consumer Cooperative of the Central Chestnut Bureau of the Ministry of Economic Affairs (please read the back page first) Please note that this page is to be filled in again.) From Section 3, it can be seen that compared with the VAA Μ group, the Η V Λ A Μ B group has a lower lactic acid value in the blood after swimming at a load of 30 minutes. Figure 4 and Figure 5 show that the blood glucose and free fatty acid in the blood are administered by HVAAMB. It shows that the value is deliberately high. From the above results, it is shown that HVAAM can reduce the exercise load caused by throbbing more than νΛΑM. Test Example 3 (Suppresses the change of amino acid composition in the blood and improves its retention effect) Music Standard Common Order National Standard (CNS) Λ4 specification (210/297 mm) 18 3 8 6 3 5 413633 A7 B7 V. Description of the invention (1 7) This test was confirmed by the mole as a test animal before exercise Administration of HVAAM can inhibit the decrease of amino acid concentration in blood during exercise. This test was performed according to the methods described in the literature (refer to J. Ben J.

Phys. Fitness Sportes Med. 1995, 44:225〜238頁)。 亦即使用鼴鼠(雄鼠,ddy, 5週龄,毎群10隻)為試驗動 物,在室溫下禁食16小時後,將表2所記載之HVAAHB, CAAM(酪朊胺基酸混合物)或蕕萄糖分別調裂成之1.8重置 %水溶液以及蒸蹓水,按照37.5pl/g體重之量經口投與後 ,在室溫下休息30分鐘。然後在流水池中令之游泳30分鐘 。測定游泳後鼷鼠血掖中總胺基酸濃度之減少情形。其結 果示於第6圖5以無投與群(投與蒸蹓水群)之對照,各營 養液投與群之血液中各胺基酸濃度之變動情形示於第7圖 0 由第6圖中可知,投與HVAAMB時,因運動而迪成的血 液中胺基酸(總胺基酸)濃度之降低情形較之CAAM投與群而 言,減少1 / 2 ;和葡匍糖投與群比較而言.減少1 / 2 . 3 7 ; 和水投與群比較而言,也减少]/ 2 . 1。 經濟部中央標隼局員工消费合作社印^ 投與HVAAMB時,對濃度會降低的胺基酸而言,如第7 圖所示,精胺酸,組胺酸,甲碕胺,天冬胺酸等均僅稍有 減少,對其他胺基酸而言,恃別是甘胺酸.離胺酸,纈胺 酸,.想胺酸和蘇胺酸等,與(:A AM或涵萄糖投與群比較,顯 示濃度降低較少。此乃血液中非Sg化脂防酸澳度之上升造 成促進脂肪酸之氛化,在TCA代謝環中,這些胺基酸之利 用被抑制之結果。_ 本纸伕尺度適用中國國家標窣(CNS ) A4規格(210X 297公釐) 3 8 6 3 5 (请先閲讀背面之注意事項再填寫本頁} 1 9 本 ΐ;α'·': ;ττ·χ 原1:質内容 經濟部中夬樣隼局員工消費合作社印获 附件Phys. Fitness Sportes Med. 1995, 44: 225 ~ 238). That is, using mole rats (male rats, ddy, 5 weeks old, and 10 mole groups) as test animals. After fasting for 16 hours at room temperature, the HVAAHB, CAAM (tyrosine amino acid mixture) described in Table 2 was used. ) Or glucosamine were adjusted to 1.8 reset% aqueous solution and distilled mash, respectively, after oral administration at an amount of 37.5 pl / g body weight, rest at room temperature for 30 minutes. Then let it swim for 30 minutes in a flowing pool. The reduction of total amino acid concentration in the blood mole of mole rats after swimming was measured. The results are shown in FIG. 6 and FIG. 5 is a comparison of the non-administration group (administration of steamed water group). The change in the concentration of each amino acid in the blood of each nutrient solution administration group is shown in FIG. 7. It can be seen from the figure that when HVAAMB is administered, the decrease in the concentration of amino acids (total amino acids) in the blood caused by exercise is reduced by 1/2 compared with the CAAM administration group; and the administration of glucosamine Group comparison. Reduced by 1/2. 3 7; compared with water investment and group, also decreased] / 2.1. Printed by the Consumers' Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs ^ When HVAAMB is administered, for amino acids whose concentration will decrease, as shown in Figure 7, arginine, histidine, formamide, aspartic acid These are only slightly reduced. For other amino acids, it is not glycine, lysine, valine, amino acid, threonine, etc., and (: A AM or glucose investment Compared with the group, it shows that the concentration decreases less. This is the increase of the non-Sg lipids in the blood and the increase in the degree of acid and acid resistance, which promotes the aromatization of fatty acids. In the TCA metabolism ring, the use of these amino acids is inhibited. Paper scale is applicable to China National Standard (CNS) A4 (210X 297 mm) 3 8 6 3 5 (Please read the notes on the back before filling out this page} 1 9 ΐ; α '·':; ττ ·· χ Original 1: Attachment printed by Employee Consumer Cooperatives of the Ministry of Economic Affairs of China

(抑制血液中胺基酸組成之變化並提升其保持效果) 本試驗乃藉家鼠為試驗動物,證實運動前投與VAAM可 抑制®動時血液中按基酸S度降低之效果。 以家鼠(Sprague Dawley rats,雄鼠,6遇龄,每群 3隻,平均體重為190g)為試驗動物,經禁食一夜後,將 表2所示从64»,04丨》&lt;(酪朊胺基酸混合物)調製成3.8重董 *之水溶液或蒸《水0.4·丨經口投與,然後在室租下休息 30分鐘。繼之.藉傾斜7°的馬達驅勡蓮動設備(每分鐘 23公分)抱步90分鐘。分别在投舆前30分鐘、抱步開始時 、雎步45分鏡時、抱完90分鐘時分別採取血液試料,鼸定 其乳酸、«萄糖,及非酯化脂肪酸(KEFA)濃度。非抱步群 則除了未抱步外,其他完全施舆苘樣處理並進行同樣的分 析。结果分別示於第8園〜第12鼸。 第8圏〜第10圖示投舆VAAM, CAAM或蒸皤水對於家鼠 血掖中《萄糖義度,血掖中乳酸《度及血液中非酯化脂肪 酸濃度之影《。第8圈〜第10鼷中,U)示抱步群,(b)示 非抱步群。星形符St表舆VAAM投輿群比較杲顯示有意差異 (P&lt;0 . 05)之结果。 由第8圃&lt;a)可知,血液中《菊糖濃度,以CAAM或蒸 籣水投與群顴示稍离情形,但鶄抱步45分鐘及90分鐘後卽 顯示有意義的降低。相對而言,VAAH投與群在抱步45分鏟 時不會降低,抱步90分饞後也較之其他之投舆群顯示有意 差異(p&lt;〇.05)的較离结果。非抱步群[第8黼(b)]之血液 本紙張尺度遑用中國囷家標準(CNS)A4况格(210X297公釐) 20{修正頁) 38635 (請先閲讀背面之注意事項再填寫本頁} ^13633 A7 B7 經濟部中央標準局員工消费合作社印敢 五、發明説明( 1 9 ) 1 1 中 萄 糖 濃 度 未 顯 示 有 意 差 異 (p&lt;0 .05 ) 之 變 化 0 1 1 I 另 外 ί 由 第 9 圖 U)可知, 對血液中乳酸濃度而言, 1 1 C A A Μ或 蒸 餾 水 投 與 群 經 咆 步 45分鐘 即有 Μ 差 異 (P &lt; 0 .05 ) 的 I I 請 1 升 高 1 咆 步 90分 鐘 後 即 降 低 〇 相對 而言 1 V AAM 投 與 群 看 不 先 閱 1 1 讀 1 1 出 有 意 差 異 (ρ &lt; 0 ‘ 0 5) 的 變 化 0 非抱 步群 [第9 圖( b) ]之血 背 I 之 ί 液 中 乳 酸 濃 度 無 有 »*r- 思 差 異 的 變 化。 注 意 1 事 1 又 由 第 1 0 圖 可 知 1 血 液 中 非酯 化脂 肪 酸 濃 度 皆 在 投 與 項 再 1 1 I 刖 (0 時) 因 林 食 而 降 低 ) 但 經 咆步 後, Cfl AM及 V A AM投 與 群 寫( 本 / 育 1 顯 示 有 葸 差 異 的 升 高 t 4 5分 鐘 後VAAH投 與 群 較 之 G A A Η ίδ 與 ί 群 顯 示 有 意 差 異 的 較 高 值 0 非 抱步 群之 血 掖 中 非 酯 化 脂 肪 1 1 酸 度 並 無 有 意 差 異 的 變 化 [參照第10圖(b)]。 1 1 第 11 圖 和 第 12 IBI 國 示 投 與 V A AH , C AAM 或 蒸 脯 水 對 於 m 鼠 訂 I 血 液 中 胺 基 酸 濃 度 之 影 坻 效 果 。第 1 1圖 和 第 12圖 中 1 黑 線 I 條 示 V A AM 投 與 群 斜 综 條 示 C A AH 投 與群 9 白 综 條 示 蒸 踊 水 1 1 I 投 與 群 之 血 液 中 各 胺 基 酸 濃 度 0 1 1 ( % 第 11 圖 之 抱 步 群 中 i (a )示投與前, ( b ) 示 投 與 30 分 鐘 V 1 (咆步0 分鐘), (C )示咆步4 5分鐘後及(d ) 示 咆 步 90 分 m 後 1 1 之 血 液 中 胺 基 酸 組 成 C 1 1 第 12 圖 之 非 抱 步 群 中 » (B )示投與前, (b )示 投 與 30分 1 I 鐘 後 (c)示投與7 5分鐘後, ⑷示 投與 1 20分鐘後血液中 • 1 1 | 之 胺 基 酸 組 成 0 星 形 符 號 表 示 與V A AM投 與 群 比 較 顯 示 有 意 1 Ί I 差 異 (P &lt; 0 ,0 5) 之 結 果 C 1 1 I 由 第 11 圖 (a )和第1 2圖( a ) 可知 ,在 试 驗 液 投 與 前 r 三 1 1 群 間 之 血 液 中 胺 基 酸 濃 度 並 無 有意 差異 C 1 1 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 2 1 3 3 6 3 5 413633 A7 B7 五、發明説明(20) 投與30分鐘後,咆步群之家鼠血液中之胺基酸濃度顯 示有意上升。但是在VAAM投與群中,麩胺酸,甲碕胺酸和 胱胺酸没有升高,CAAM投與群之胱胺酸和甘胺酸也未升高 [參照第1 1圖(b )]。 投與VAAM或CAAM 30分鐘後的未咆步群之家鼠血液中 胺基酸滠度之升高情形與投與30分鐘後之咆步群家鼠情形 相同[參照第12圖(b)]。 抱步45分鐘後,各胺基酸度除VAAM投與群之酷胺酸外 ,所有試驗群皆顯示下降结果[參照第11圖(c)]。VAAM投 與群的甘胺酸,丙胺酸,纈胺酸,餑胺酸,酪肢酸,離胺 酸和脯胺酸濃度較之蒸蹓水投與群顯示有意之較高值。S 外,VMM投與群之甘胺酸,榦肢酸,酪胺酸和脯胺酸模度 也較之CAAH投與群顯示有意之較高值。CAAM投與群之纈胺 酸和離胺酸濃度較之投與蒸餾水的對照群顯示有意之較离 值;但是,與VAAM投與群比較,沒有一種胺基酸顳示較高 值者。 經濟部中央標準局負工消费合作社印災 (請先閲讀背面之注意事項再填寫本頁) 在非抱步群中,VAAM投與群的丙胺酸和離胺酸濃度並 無升高[參照第12圖(c)]。在VAAH投與群中.非咆步群的 酪胺酸港度較之抱步者為低;在C/UM或蒸辎水投與群中, 咆步群的酩胺酸溏度較之非咆步群者為高值。 咆完時.VAAM投與群的纈胺酸,白胺酸.絲按酸.蘇 胺酸,酪胺酸和離胺酸濃度較之抱步45分_後之值比較結 果幾無下降[參照第11圖(d)]。VAAM投與群的P按酸,酪 _胺酸,離胺酸和脯胺酸濃度較之蒸蹓水投與群抱步90分鐘 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ 297公釐) 2 2 3 8 6 3 5 413633 A7 B7 五、發明説明(21 ) 後之值顯示有意之离值。在非咆步群中,VAAM投與群的蘇 胺酸和脯胺酸濃度較之蒸蹓水投與120分鐘的抱步群者為 高值。 由上述結果可知,葙投與VAAM能抑制用運動而産生的 胺基之消耗,顯示VAAM能抑制因運動所誘發的疲勞效果。 因此,本發明之組成物可以補充因激烈運動所産生之 血液中胺基酸之減少,具有提升運動機能,減輕運動疲努 和恢愎疲勞等之功能。又.锗投與本發明組成物可抑制因 a動而發生之胺基酸的消耗、能抑制因浬動所誘發之疲勞 等效果。因此,在産業上深具應用可行性。 (讀先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消费合作社印製 本紙張尺度適用中國國家標準(CNS ) Λ4规格(21〇X2y7公釐) 23 38635(Inhibits the change of amino acid composition in the blood and improves its retention effect) This test is to use domestic rats as experimental animals to prove that the administration of VAAM before exercise can inhibit the decrease of the degree of S acid in the blood during exercise. Domestic rats (Sprague Dawley rats, males, 6 years old, 3 per group, average weight 190g) were used as experimental animals. After fasting overnight, the table shown in Table 2 was changed from 64 », 04 丨" &lt; ( The tyrosine amino acid mixture) is prepared into an aqueous solution of 3.8 wt.% Or steamed with "water 0.4 · 丨 and administered orally, and then rested at room rent for 30 minutes. Followed by a 7 ° motor driving the lotus lotus device (23 cm per minute) for 90 minutes. Blood samples were taken 30 minutes before the show, at the beginning of Baobu, at the 45th minute of Liaobu, and at 90 minutes after the hug, to determine their lactic acid, glucose, and non-esterified fatty acid (KEFA) concentrations. The non-holding group except the non-holding group is completely treated in the same way and performs the same analysis. The results are shown in the 8th round to the 12th round. The eighth to tenth figures show the effects of VAAM, CAAM, or steamed water on the blood glucose level of glucosamine, blood lactic acid, and the concentration of non-esterified fatty acids in blood. On the eighth to tenth laps, U) shows the step group and (b) shows the non-step group. The star character St indicates that the comparison of the VAAM voting group shows the result of an intentional difference (P &lt; 0.05). From the eighth nursery, <a), it can be seen that the concentration of inulin in the blood was slightly off when the group was administered with CAAM or steamed water, but it showed a significant decrease after 45 minutes and 90 minutes. Relatively speaking, the VAAH investment group did not decrease with 45 minutes of shovel. After 90 minutes of shovel, compared with other investment groups, the VAAH group showed intentional difference (p &lt; 0.05). The blood paper size of the non-holding group [No. 8 (b)] uses the Chinese Standard (CNS) A4 (210X297 mm) 20 {correction page) 38635 (Please read the notes on the back before filling This page} ^ 13633 A7 B7 The Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs of the People's Republic of China Yin Gan V. Description of Invention (1 9) 1 1 Changes in glucose concentration did not show an intentional difference (p &lt; 0.05) 0 1 1 I In addition ί From Figure 9U), it can be seen that, for the lactic acid concentration in the blood, 1 1 CAA Μ or distilled water is administered to the group for 45 minutes and there is a difference in Μ (P &lt; 0.05). Please increase 1 and 1 After 90 minutes, it will decrease. Relatively speaking, the 1 V AAM investment group cannot be read first. 1 1 read 1 1 changes with intentional differences (ρ &lt; 0 '0 5). 0 non-holding group [Figure 9 (b )] There is no change in the concentration of lactic acid in the blood of I】. Note 1 thing 1 and Figure 10 shows that 1 the concentration of non-esterified fatty acids in the blood are all administered again 1 1 I 刖 (at 0) due to forest food reduction) but after roaring, Cfl AM and VA AM Written group writing (Ben / Yu1 shows an increase in the difference between t4 and 5 minutes later. The VAAH dosing group shows a higher value compared to GAA 5δ and ί group. The blood of non-holding group is not high. Central Africa There is no intentional difference in the acidity of the esterified fat 1 1 [refer to Figure 10 (b)]. 1 1 Figure 11 and 12 IBI states that the administration of VA AH, C AAM or steamed preserved water for m rat I blood The effect of the concentration of amino acids in the middle. Figures 1 1 and 12 1 The black line I shows the VA AM application group diagonally integrated bars CA AH the application group 9 white integrated bars shows steamed water 1 1 I The concentration of each amino acid in the blood of the administration group is 0 1 1 (% I (a) before the vote, (b) after 30 minutes V 1 (0 minutes), (C) after 4 5 minutes, and (d) after 90 minutes m The amino acid composition in the blood of 1 1 is C 1 1 Figure 12 in the non-holding group »(B) shows before administration, (b) shows 30 minutes after administration 1 I minutes later (c) shows administration 7 5 After 1 minute, ⑷ indicates that after administration for 20 minutes • 1 1 | amino acid composition in the blood is 0. A star symbol indicates that compared with the VA AM administration group, an intentional 1 Ί I difference (P &lt; 0, 0 5) is shown. Results C 1 1 I From Figure 11 (a) and Figure 12 (a), it can be seen that there was no intentional difference in the amino acid concentration in the blood between the r r 3 1 1 groups before the test solution was administered. Paper size applies Chinese National Standard (CNS) A4 (210X297 mm) 2 1 3 3 6 3 5 413633 A7 B7 V. Description of the invention (20) 30 minutes after administration, the amines in the blood of rats The base acid concentration showed a deliberate increase. However, in the VAAM administration group, glutamic acid, formamide and cystine did not increase, and the CAAM administration group did not increase cystine and glycine [see Figure 11 (b)] . After 30 minutes of administration of VAAM or CAAM, the increase in amino acid levels in the blood of non-growth group rats was the same as that of 30-minus group rats [see Figure 12 (b)] . After 45 minutes of holding step, all the test groups except for the glutamic acid of the VAAM administration group showed a decrease in results [refer to FIG. 11 (c)]. The concentrations of glycine, alanine, valine, acetic acid, butyric acid, lysine, and proline in the VAAM administration group showed intentionally higher values than the steamed administration group. In addition, the glycine, dry limb acid, tyrosine, and proline moduli of the VMM administration group also showed intentionally higher values than the CAAH administration group. The concentration of valine and lysine in the CAAM administration group showed a deliberate deviation compared to the control group administered with distilled water; however, none of the amino acids showed a higher value compared to the VAAM administration group. Disaster printed by the Consumers' Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling this page). In the non-hospital group, the concentrations of alanine and lysine in the VAAM administration group did not increase [Ref. 12 (c)]. In the VAAH administration group, the tyrosine acidity degree of the non-Naobu group is lower than that of the pacemaker; in the C / UM or steamed water administration group, the amino acid degree of the Niaobu group is lower than that of the non-Naobu group. Roaring steps are high. At the end of the day, the concentrations of valine, leucine, silk, acid, threonine, tyrosine, and lysine in the VAAM administration group did not decrease compared to the values after 45 minutes. Figure 11 (d)]. The concentration of P in VAAM administration group is based on the concentration of acid, tyrosine, lysine and proline compared with steamed water administration. The application of the group is 90 minutes. The paper size is applicable to Chinese National Standard (CNS) A4 specification (210 × 297) (Centi) 2 2 3 8 6 3 5 413633 A7 B7 5. The value after the description of the invention (21) shows the intentional deviation. In the non-crowding group, the concentrations of threonine and proline in the VAAM administration group were higher than those in the Baobu group treated with steamed water for 120 minutes. From the above results, it can be seen that the administration of VAAM can suppress the consumption of amine groups caused by exercise, and shows that VAAM can suppress the fatigue effect caused by exercise. Therefore, the composition of the present invention can supplement the reduction of amino acids in blood caused by intense exercise, and has the functions of improving exercise performance, reducing exercise fatigue and restoring fatigue. In addition, the administration of germanium to the composition of the present invention can suppress the consumption of amino acids caused by agitation, and can suppress the fatigue induced by agitation. Therefore, it has deep application feasibility in industry. (Read the precautions on the back before you fill out this page) Printed by the Central Consumers' Bureau of the Ministry of Economic Affairs, Consumer Cooperatives This paper is sized for the Chinese National Standard (CNS) Λ4 (21〇2y7mm) 23 38635

Claims (1)

正 H3 烦請委員明示:入5:4:正後是否變史原實質内容 附件二Zheng H3, members are kindly requested to indicate clearly: Entry 5: 4: Whether the original content of the original history after the annex is attached. 第86100261號專利申請講 申請專利範圃修正本(88年8月24曰)—種胺基酸組成物,其特戡係含有下列莫耳比率之下 列胺基酸所組成: 經濟部中央標準局員工福利委員會印製 2 脯 胺 酸 12 * 6〜 23 . 4 莫 耳 丙 胺 酸 8 • 4〜 1 5 _ 6 莫 耳 甘 胺 酸 13 _ 3〜 24 . 9 莫 耳 纈 胺 酸 8 .2〜 15. 4 莫 耳 蘇 胺 酸 5 • 0〜 9 4 莫 耳 白 胺 酸 4 ‘ .3〜 8 . 1 莫 耳 組 胺 酸 1 ‘ ,8〜 1 1 _ 9 莫 耳 絲 胺 酸 1 . ,7〜 3 . 3 莫 耳 離 胺 酸 6 _ 0〜 11. 2 奠 耳 異 白 胺 酸 3 _ ,1〜 5 . 9 m 耳 麩 胺 酸 2 - .2〜 10. 4 莫 耳 精 胺 酸 2 . 4 . 6 莫 耳 苯 丙 胺 酸 2 . 6〜 5 . 0 莫 耳 賂 肢 酸 4 . 2〜 7 . 8 萁 耳 色 胺 酸 1 . 5〜 2 . 9 其 耳。 如申請專利範圍第1項之胺基酸組成物 有下列莫耳比率之下列胺基酸所組成者 脯胺酸 14.4〜21.6莫耳丙胺酸 9.6〜14.4冥耳甘胺酸 15.2〜23.0奠耳 其中,係含 本紙張尺度通用中國國家標準(CNS)A4規格(210X297公A) 1 3 8 6 3 5 正 H3 烦請委員明示:入5:4:正後是否變史原實質内容 附件二The patent application No. 86100261 refers to the amended version of the patent application (August 24, 88)-a kind of amino acid composition, which is specifically composed of the following amino acids containing the following molar ratios: Central Bureau of Standards, Ministry of Economic Affairs Printed by the Employee Welfare Committee 2 Proline 12 * 6 ~ 23. 4 Mole Alanine 8 • 4 ~ 1 5 _ 6 Mole Glycine 13 _ 3 ~ 24. 9 Mole Valine 8. 2 ~ 15 4 Molesine 5 • 0 ~ 9 4 Moles Leucine 4 '.3 ~ 8. 1 Moles Histidine 1 ′, 8 ~ 1 1 _ 9 Mols Leucine 1, 7 ~ 3.3 Mole lysine 6 _ 0 to 11. 2 Mole isoleucine 3 _, 1 to 5.9 m glutamic acid 2-. 2 to 10. 4 Mole arginine 2.4 6 Mol Phenylalanine 2. 6 ~ 5. 0 Mol Phenylalanine 4. 2 ~ 7.8 8 Ear Pyramine 1. 5 ~ 2. 9 Its ears. For example, the amino acid composition of the first patent application scope has the following molar ratios. The following amino acids are composed of proline 14.4 to 21.6 mol alanine 9.6 to 14.4 glutarine 15.2 to 23.0 It contains the standard Chinese National Standard (CNS) A4 (210X297 male A) of this paper standard. 1 3 8 6 3 5 H3 Members are kindly requested to state clearly: Enter 5: 4: Will the original substance of the original content be changed after attachment? 第86100261號專利申請講 申請專利範圃修正本(88年8月24曰)—種胺基酸組成物,其特戡係含有下列莫耳比率之下 列胺基酸所組成: 經濟部中央標準局員工福利委員會印製 2 脯 胺 酸 12 * 6〜 23 . 4 莫 耳 丙 胺 酸 8 • 4〜 1 5 _ 6 莫 耳 甘 胺 酸 13 _ 3〜 24 . 9 莫 耳 纈 胺 酸 8 .2〜 15. 4 莫 耳 蘇 胺 酸 5 • 0〜 9 4 莫 耳 白 胺 酸 4 ‘ .3〜 8 . 1 莫 耳 組 胺 酸 1 ‘ ,8〜 1 1 _ 9 莫 耳 絲 胺 酸 1 . ,7〜 3 . 3 莫 耳 離 胺 酸 6 _ 0〜 11. 2 奠 耳 異 白 胺 酸 3 _ ,1〜 5 . 9 m 耳 麩 胺 酸 2 - .2〜 10. 4 莫 耳 精 胺 酸 2 . 4 . 6 莫 耳 苯 丙 胺 酸 2 . 6〜 5 . 0 莫 耳 賂 肢 酸 4 . 2〜 7 . 8 萁 耳 色 胺 酸 1 . 5〜 2 . 9 其 耳。 如申請專利範圍第1項之胺基酸組成物 有下列莫耳比率之下列胺基酸所組成者 脯胺酸 14.4〜21.6莫耳丙胺酸 9.6〜14.4冥耳甘胺酸 15.2〜23.0奠耳 其中,係含 本紙張尺度通用中國國家標準(CNS)A4規格(210X297公A) 1 3 8 6 3 5 413633 H3 經濟部中央標準局員工福利委員會印製 酸酸酸酸酸酸 睽胺 按按按 按 RMN Huo ODnM dhu 顯蘇白組絲鑪 含 係 中 其 ο &gt; : 耳耳 耳耳耳 耳耳耳 耳耳耳 耳物者 耳耳耳 耳耳耳 莫莫莫莫莫莫冥莫萁莫莫莫成成萁奠其莫其莫 275004462627^^821008 487130594472^^931386 1 1 1 - . fc ir J 基酸 胺基 之胺 項列 1 下 第之 _ 率 範比 利耳 專莫 請列 申下 如有 3 酸 胺酸酸 白胺胺 異麩精 酸 胺酸酸 丙胺胺 苯賂色 ---------- 酸 酸酸酸酸酸酸酸酸酸胺酸 胺胺 胺胺胺 胺胺胺 胺白胺 脯丙甘纈蘇白組絲離異麩 ---------- 耳 莫 耳耳 其莫 耳 耳 莫其 本紙張尺度適用中國國家樣準(CNS)A4規格(210X297公#) 386 3 5 413633 經濟部中央標準局員工福利委員會印製 精 胺 酸 3 . 1〜 3.9 莫 耳 苯 丙 胺酸 3 . 4〜 4.2 莫 耳 賂 胺 酸 5 · 4〜 6 . 6 其 耳 色 胺 酸 1 . 9〜 2 . 5 舆 耳。 4_如申請專利範鼸第1項之胺基酸组成物,其中,組胺 酸之莫耳比率係在6.4〜11.9莫耳,麩胺酸之莫耳比率 係在5.6〜10·4舆耳者。 5. 如申請專利範匾第1項至第4項任意一項之胺基酸組 成物,係用Κ製造補液者。 6. 如申請專利範圍第1項至第4項任意一項之胺基酸組 成物,係用於製造具有補充因激烈運動所引起之血液 中減少的胺基酸、提升運動櫬能、減輕運動後之疲勞 和恢復疲勞等效果的胺基酸組成物。 7· —棰含有下列莫耳比率之下列胺基酸所組成胺基酸組 成物,係用於製造具有補充因瀲烈運動所引起之血液 中滅少之胺基酸,提升運動櫬能,減輕運動後之疲勞 和恢復疲勞等效果的胺基酸組成物: 脯 胺 酸 12. 6〜 23 • 4 莫 耳 丙 胺 酸 4 . 2〜 7 i .8 莫 耳 甘 胺 酸 1 3 . 3〜 24 , ,9 莫 耳 纈 胺 酸 4 . 1〜 7 . ,7 其 耳 蘇 胺 酸 5 . 〇〜 9 · 4 莫 耳 白 胺 酸 4 . 3〜 8 . 1 莫 耳 組 胺 酸 1 . 8〜 3 . 8 η 耳 絲 胺 酸 1 . 7〜 3 . 3 莫 耳 本紙張尺度適用中a國家揉準(CNS)A4規格(210 X 297公董) 3 38635 413633 離 胺 酸 6 • 0〜 11 .2 奠 耳 異 白 胺 酸 3 .1〜 5 .9 舆 耳 麩 胺 酸 2 , 1 2〜 4 , .2 萁 耳 精 胺 酸 2 . • 4〜 4 , .6 莫 耳 苯 丙 胺 酸 2 , ,6〜 5 . ,0 莫 耳 賂 胺 酸 4 . ,2〜 7 · 8 莫 耳 色 胺 酸 1 . 5〜 2 . 9 莫 耳。 8. 如申請專利範圃第1項至第4項任意一項之胺基酸組 成物,偽用於製造具有抑制血液中胺基酸濃度之變化 並提升其保持效果之胺基酸組成物。 9. 如申請專利範圍第7項之胺基酸組成物,係用於製造 具有抑制血液中胺基酸濃度之變化並提升其保持效果 之胺基酸姐成物者。 經濟部中央標準局貝工福利委員會印製 本紙張尺度適用中國S家標準(CNS )A4規格(210 X 297公董) 4 3 863 5The patent application No. 86100261 refers to the amended version of the patent application (August 24, 88)-a kind of amino acid composition, which is specifically composed of the following amino acids containing the following molar ratios: Central Bureau of Standards, Ministry of Economic Affairs Printed by the Employee Welfare Committee 2 Proline 12 * 6 ~ 23. 4 Mole Alanine 8 • 4 ~ 1 5 _ 6 Mole Glycine 13 _ 3 ~ 24. 9 Mole Valine 8. 2 ~ 15 4 Molesine 5 • 0 ~ 9 4 Moles Leucine 4 '.3 ~ 8. 1 Moles Histidine 1 ′, 8 ~ 1 1 _ 9 Mols Leucine 1, 7 ~ 3.3 Mole lysine 6 _ 0 to 11. 2 Mole isoleucine 3 _, 1 to 5.9 m glutamic acid 2-. 2 to 10. 4 Mole arginine 2.4 6 Mol Phenylalanine 2. 6 ~ 5. 0 Mol Phenylalanine 4. 2 ~ 7.8 8 Ear Pyramine 1. 5 ~ 2. 9 Its ears. For example, the amino acid composition of the first patent application scope has the following molar ratios. The following amino acids are composed of proline 14.4 to 21.6 mol alanine 9.6 to 14.4 glutarine 15.2 to 23.0 It contains the standard Chinese National Standard (CNS) A4 (210X297 male A) of this paper standard. 1 3 8 6 3 5 413633 H3 Printed by the Staff Welfare Committee of the Central Standards Bureau of the Ministry of Economic Affairs RMN Huo ODnM dhu Xiansubai group wire furnace containing ο &gt;:> Ear ear ear ear ear ear ear ear ear ear ear ear ear ear ear ear momomomomomomomomomomomo Cheng Chengxian Mo Qimo 275004462627 ^^ 821008 487130594472 ^^ 931386 1 1 1-. Fc ir J Amino acid amino group of the amines listed in the first _ the first _ rate Fan Billiards please list if there is any 3 acid amino acid leucoamine isoglutamic acid amino acid propylamine amine benzene color ---------- acid acid acid acid acid acid acid acid amino acid Amino Leucamine Proglycerol and Supai White Silk Isogluten ------------ Ear Morge Morge Morge China National Standard (CNS) A4 Specification (210X297 公 #) 386 3 5 413633 Employee Welfare Committee of the Central Standards Bureau of the Ministry of Economic Affairs printed arginine 3. 1 ~ 3.9 mol phenylalanine 3. 4 ~ 4.2 molamine 5 · 4 ~ 6. 6 Its ear tryptophan is 1.9 ~ 2.5. 4_ The amino acid composition according to item 1 of the patent application, wherein the molar ratio of histidine is 6.4 to 11.9 mol, and the molar ratio of glutamic acid is 5.6 to 10.4 mol By. 5. If the amino acid composition of any one of items 1 to 4 of the patent plaque is applied, those who use K to make fluid replacement. 6. The amino acid composition according to any one of claims 1 to 4 of the scope of patent application, is used to produce supplements that reduce the amino acids in blood caused by intense exercise, improve athletic performance, and reduce exercise. Amino acid composition with effects such as subsequent fatigue and recovery from fatigue. 7 · —The amino acid composition composed of the following amino acids with the following molar ratios is used to manufacture amino acids that supplement the elimination of amino acids in the blood caused by vigorous exercise, improve exercise energy, and reduce Amino acid composition for fatigue after exercise and recovery from fatigue effects: Proline 12.6 ~ 23 • 4 Mol Alanine 4. 2 ~ 7 i .8 Mol Glycine 1 3. 3 ~ 24, , 9 mole valinic acid 4.1 ~ 7., 7 its ear threonine 5.0.0 ~ 9 · 4 mole leucine acid 4.3 ~ 8. 1 mole histamine 1.8 ~ 3. 8 η Ear serine 1. 7 ~ 3. 3 The size of this paper is suitable for China National Standards (CNS) A4 (210 X 297 mm) 3 38635 413633 Lysine 6 • 0 ~ 11.2 Otisoleucine 3 .1 ~ 5.9 .9 glutamic acid 2, 1 2 ~ 4, .2 arginine 2. • 4 ~ 4, .6 mole phenylalanine 2, 6 ~ 5 .0 Moral amine 4., 2 ~ 7 · 8 Moral tryptophan 1.5. 2 ~ 2.9 Mor. 8. If the amino acid composition of any one of items 1 to 4 of the patent application is used, it is pseudo-used to produce an amino acid composition that suppresses changes in the concentration of amino acids in the blood and improves its retention effect. 9. The amino acid composition according to item 7 of the scope of patent application is for the manufacture of amino acid sister products that can suppress the change of the amino acid concentration in the blood and improve its retention effect. Printed by the Shell Welfare Committee of the Central Standards Bureau of the Ministry of Economic Affairs This paper is sized according to China Standards (CNS) A4 (210 X 297 public directors) 4 3 863 5
TW086100261A 1996-01-09 1997-01-09 Amino acid composition TW413633B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP154796 1996-01-09
JP00229597A JP3814683B2 (en) 1996-01-09 1997-01-09 Amino acid composition

Publications (1)

Publication Number Publication Date
TW413633B true TW413633B (en) 2000-12-01

Family

ID=26334786

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086100261A TW413633B (en) 1996-01-09 1997-01-09 Amino acid composition

Country Status (2)

Country Link
JP (1) JP3814683B2 (en)
TW (1) TW413633B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017000309U1 (en) 2016-08-05 2017-01-30 Sunny Wheel Industrial Co., Ltd. Basket mounting device
CN116651533A (en) * 2023-05-26 2023-08-29 苏建桦 Composition for increasing telomere length and method for preparing the same

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855727B2 (en) 2000-12-04 2005-02-15 Yaizu Suisankagaku Industry Co., Ltd. Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect
CA2412789C (en) 2001-04-24 2010-05-04 Taiyo Kagaku Co., Ltd. Compositions for improving mental concentration
KR20050107573A (en) * 2003-01-10 2005-11-14 유니버시타이트 반 마스트리히트 Compositions and methods for improving the condition of patients suffering from copd and other diseases
JP4528925B2 (en) 2003-05-30 2010-08-25 独立行政法人理化学研究所 Amino acid composition and fluid replacement
JPWO2005027898A1 (en) * 2003-09-19 2007-11-15 独立行政法人理化学研究所 Amino acid composition
AU2005278649B8 (en) 2004-09-02 2010-07-22 Cosmo Ala Co., Ltd. Constitutional function-improving agents
JP5604673B2 (en) * 2005-01-31 2014-10-15 隆宣 山本 Composition for recovery or prevention of fatigue of central nervous system
EP1983849B1 (en) * 2006-01-20 2013-04-03 Innova Food AB A food composition comprising amino acids
CN101454000A (en) * 2006-06-13 2009-06-10 明治乳业株式会社 Anti-fatigue agent containing amino acid composition
CN101626764B (en) * 2007-02-28 2012-03-07 株式会社明治 Amino acid composition
JP5173230B2 (en) * 2007-04-03 2013-04-03 株式会社明治 Amino acid composition and food and drink
US20100267794A1 (en) * 2007-10-31 2010-10-21 Meiji Dairies Corporation Anti-fatigue agent comprising amino acid composition
EP2742938B1 (en) * 2011-08-08 2018-05-09 Ajinomoto Co., Inc. Amino-acid-containing composition for enhancing recovery from muscle fatigue

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017000309U1 (en) 2016-08-05 2017-01-30 Sunny Wheel Industrial Co., Ltd. Basket mounting device
CN116651533A (en) * 2023-05-26 2023-08-29 苏建桦 Composition for increasing telomere length and method for preparing the same
CN116651533B (en) * 2023-05-26 2024-06-11 苏建桦 Preparation method of composition for improving telomere length

Also Published As

Publication number Publication date
JP3814683B2 (en) 2006-08-30
JPH09249556A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
TW413633B (en) Amino acid composition
JP4528925B2 (en) Amino acid composition and fluid replacement
JP6255079B2 (en) Rapid-acting oral arginine level oral preparation containing citrulline and arginine
JP2590423B2 (en) Food material enriched in γ-aminobutyric acid
US6287757B1 (en) Amino acid-trehalose composition
JP2873497B2 (en) Lipid metabolism regulator
US8445466B2 (en) Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
CA2242646C (en) Amino acid composition
JP4596304B2 (en) Growth hormone secretion promoting composition
JP2518692B2 (en) Muscle maintenance agent, nutrient tonic, infusion agent, nutritional supplement, fatigue recovery agent and lactic acid production regulator
US20060128778A1 (en) Amino acid composition for improving central functions
JPH04278061A (en) Nutritious food
US20100168040A1 (en) Muscle fatigue remedy
EP0655244B2 (en) Amino acid composition for the treatment of infections
TWI772922B (en) Use of morchella active substance
JP4009682B2 (en) Adrenaline and noradrenaline secretion promoting composition
JP3553992B2 (en) Metabolic regulator
JPWO2007077995A1 (en) Muscle bulking agent
CA2909750C (en) Liquid or semi-liquid pharmaceutical, dietary or food composition free of bitterness containing an arginine salt
JP5887893B2 (en) Oral solution
US20170252298A1 (en) Performance-Enhancing Nasal Irrigation
EP0938850A1 (en) Food or pharmaceutical composition and preparations containing the same
BE882259A (en) SYNERGISTIC PHARMACEUTICAL COMPOSITIONS AND THEIR PREPARATION METHOD
FR2582512A1 (en) Energy-generating composition, for dietetic or medical use, combining an amino acid and ascorbic acid with synergistic effect.

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees